

# Evidence Regarding Human Papillomavirus Testing in S Cancer

Vaccine

30, F88-F99

DOI: [10.1016/j.vaccine.2012.06.095](https://doi.org/10.1016/j.vaccine.2012.06.095)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Cervical cancer – should we abandon cytology for screening?. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 558-559.	12.5	5
2	Nucleic Acid Tests for the Detection of Alpha Human Papillomaviruses. <i>Vaccine</i> , 2012, 30, F100-F106.	1.7	91
3	Answering human papillomavirus vaccine concerns; a matter of science and time. <i>Infectious Agents and Cancer</i> , 2013, 8, 22.	1.2	6
4	HPV-based Tests for Cervical Cancer Screening and Management of Cervical Disease. <i>Current Obstetrics and Gynecology Reports</i> , 2013, 2, 76-85.	0.3	15
5	Understanding HPV tests and their appropriate applications. <i>Cytopathology</i> , 2013, 24, 289-308.	0.4	36
6	Barreras para la implementación de la prueba ADN-VPV como técnica de tamizaci3n primaria para c4ncer de cuello uterino en un 4rea demostrativa en Colombia. <i>Revista Colombiana De Cancerolog4a</i> , 2013, 17, 93-102.	0.0	2
7	Human Papillomavirus Infection and the Multistage Carcinogenesis of Cervical Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 553-560.	1.1	223
8	Use of a high-risk human papillomavirus <scp>DNA</scp> test as the primary test in a cervical cancer screening programme: a population-based cohort study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2013, 120, 1260-1268.	1.1	47
9	Trials and Projects on Cervical Cancer and Human Papillomavirus Prevention in Sub-Saharan Africa. <i>Vaccine</i> , 2013, 31, F53-F59.	1.7	33
10	Infrastructure Requirements for Human Papillomavirus Vaccination and Cervical Cancer Screening in Sub-Saharan Africa. <i>Vaccine</i> , 2013, 31, F47-F52.	1.7	71
11	Comprehensive Control of Human Papillomavirus Infections and Related Diseases. <i>Vaccine</i> , 2013, 31, H1-H31.	1.7	261
12	Comprehensive Control of Human Papillomavirus Infections and Related Diseases. <i>Vaccine</i> , 2013, 31, H1-H31.	1.7	272
13	Annual Papanicolaou screening for 5 years among human papillomavirus-negative women. <i>BMC Cancer</i> , 2013, 13, 379.	1.1	16
14	Comprehensive Control of Human Papillomavirus Infections and Related Diseases. <i>Vaccine</i> , 2013, 31, F1-F31.	1.7	40
15	Recommendations for Cervical Cancer Prevention in Central and Eastern Europe and Central Asia. <i>Vaccine</i> , 2013, 31, H80-H82.	1.7	15
16	Comprehensive Control of Human Papillomavirus Infections and Related Diseases. <i>Vaccine</i> , 2013, 31, G1-G31.	1.7	33
17	Human Papillomavirus Testing in Cervical Cancer Screening. <i>Obstetrics and Gynecology Clinics of North America</i> , 2013, 40, 377-390.	0.7	13
18	Chromosomal gains measured in cytology samples from women with abnormal cervical cancer screening results. <i>Gynecologic Oncology</i> , 2013, 130, 595-600.	0.6	24

#	ARTICLE	IF	CITATIONS
19	Comparison of the detection of HPV-16, 18, 31, 33, and 45 by type-specific DNA- and E6/E7 mRNA-based assays of HPV DNA positive women with abnormal Pap smears. <i>Journal of Virological Methods</i> , 2013, 194, 222-228.	1.0	14
20	Human papillomavirus testing versus repeat cytology for triage of minor cytological cervical lesions. <i>The Cochrane Library</i> , 2021, 2021, CD008054.	1.5	67
21	Triage of women with minor abnormal cervical cytology: Meta-analysis of the accuracy of an assay targeting messenger ribonucleic acid of 5 high-risk human papillomavirus types. <i>Cancer Cytopathology</i> , 2013, 121, 675-687.	1.4	36
22	Viral and Cellular Biomarkers in the Diagnosis of Cervical Intraepithelial Neoplasia and Cancer. <i>BioMed Research International</i> , 2013, 2013, 1-10.	0.9	96
23	Screening for Cervical Cancer Precursors With p16/Ki-67 Dual-Stained Cytology: Results of the PALMS Study. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1550-1557.	3.0	168
24	An Evaluation of Novel, Lower-Cost Molecular Screening Tests for Human Papillomavirus in Rural China. <i>Cancer Prevention Research</i> , 2013, 6, 938-948.	0.7	88
25	The Aptima HPV Assay Fulfills the Cross-Sectional Clinical and Reproducibility Criteria of International Guidelines for Human Papillomavirus Test Requirements for Cervical Screening. <i>Journal of Clinical Microbiology</i> , 2013, 51, 3653-3657.	1.8	52
26	Clinical Validation of the Abbott RealTime High Risk HPV Assay According to the Guidelines for Human Papillomavirus DNA Test Requirements for Cervical Screening. <i>Journal of Clinical Microbiology</i> , 2013, 51, 2409-2410.	1.8	40
27	Comparing the Cervista HPV HR Test and Hybrid Capture 2 Assay in a Dutch Screening Population: Improved Specificity of the Cervista HPV HR Test by Changing the Cut-Off. <i>PLoS ONE</i> , 2014, 9, e101930.	1.1	11
29	Magnivisualizer in the early detection of cervical neoplasia. <i>Journal of Gynecologic Oncology</i> , 2014, 25, 263.	1.0	3
31	Women's intentions to self-collect samples for human papillomavirus testing in an organized cervical cancer screening program. <i>BMC Public Health</i> , 2014, 14, 1060.	1.2	12
32	A population-based observational study comparing Cervista and Hybrid Capture 2 methods: improved relative specificity of the Cervista assay by increasing its cut-off. <i>BMC Infectious Diseases</i> , 2014, 14, 674.	1.3	12
33	The current position and the future perspectives of cervical cancer screening. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 75-92.	1.1	25
34	Vaginal self-sampling is a cost-effective way to increase participation in a cervical cancer screening programme: a randomised trial. <i>British Journal of Cancer</i> , 2014, 111, 2187-2196.	2.9	73
35	Comparative performance of novel self-sampling methods in detecting high-risk human papillomavirus in 30,130 women not attending cervical screening. <i>International Journal of Cancer</i> , 2015, 136, 646-655.	2.3	59
37	Arguments in favor of HPV testing for cervical screening and post-treatment CIN2+ monitoring. <i>Expert Review of Molecular Diagnostics</i> , 2014, 14, 245-248.	1.5	4
38	Self-Sampling for High-Risk Human Papillomavirus Detection: Future Cervical Cancer Screening?. <i>Women's Health</i> , 2014, 10, 115-118.	0.7	4
39	"I don't care whether it's HPV or ABC, I just want to know if I have cancer." Factors influencing women's emotional responses to undergoing human papillomavirus testing in routine management in cervical screening: a qualitative study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2014, 121, 1421-1430.	1.1	38

#	ARTICLE	IF	CITATIONS
40	Benefits and Risks of Cervical Cancer Screening. <i>Oncology Research and Treatment</i> , 2014, 37, 48-57.	0.8	19
41	Clinical Evaluation of a GP5+/6+-Based Luminex Assay Having Full High-Risk Human Papillomavirus Genotyping Capability and an Internal Control. <i>Journal of Clinical Microbiology</i> , 2014, 52, 3996-4002.	1.8	40
42	Cervical cancer screening: on the way to a shift from cytology to full molecular screening. <i>Annals of Oncology</i> , 2014, 25, 927-935.	0.6	74
43	Early detection of CIN3 and cervical cancer during long-term follow-up using HPV/Pap smear co-testing and risk-adapted follow-up in a locally organised screening programme. <i>International Journal of Cancer</i> , 2014, 135, 1408-1416.	2.3	33
44	Evaluation of cytology and visual triage of human papillomavirus- $\epsilon$ positive women in cervical cancer prevention in India. <i>International Journal of Cancer</i> , 2014, 134, 2902-2909.	2.3	28
45	The Natural History of Cervical Cancer in Chinese Women: Results from an 11-Year Follow-Up Study in China Using a Multistate Model. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 1298-1305.	1.1	14
46	HPV and cervical cancer. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2014, 74, 59-62.	0.6	56
47	Cross-sectional study of genital carcinogenic HPV infections in Paramaribo, Suriname: prevalence and determinants in an ethnically diverse population of women in a pre-vaccination era. <i>Sexually Transmitted Infections</i> , 2014, 90, 627-633.	0.8	21
48	Current Cervical Cancer Screening Knowledge, Awareness, and Practices Among U.S. Affiliated Pacific Island Providers: Opportunities and Challenges. <i>Oncologist</i> , 2014, 19, 383-393.	1.9	22
49	Metaprop: a Stata command to perform meta-analysis of binomial data. <i>Archives of Public Health</i> , 2014, 72, 39.	1.0	1,518
50	cobas <sup>®</sup> 4800 HPV Test, a real-time polymerase chain reaction assay for the detection of human papillomavirus in cervical specimens. <i>Expert Review of Molecular Diagnostics</i> , 2014, 14, 5-16.	1.5	21
51	Posttreatment Assessment of Women at Risk of Developing High-Grade Cervical Disease. <i>Journal of Lower Genital Tract Disease</i> , 2014, 18, 338-343.	0.9	15
52	Current cervical cancer prevention strategies including cervical screening and prophylactic human papillomavirus vaccination. <i>Current Opinion in Oncology</i> , 2014, 26, 120-129.	1.1	13
53	High-Risk and Low-Risk Human Papillomavirus and the Absolute Risk of Cervical Intraepithelial Neoplasia or Cancer. <i>Obstetrics and Gynecology</i> , 2014, 123, 57-64.	1.2	28
54	Evaluation of commercial HPV assays in the context of post-treatment follow-up: Scottish Test of Cure Study (STOCS-H). <i>Journal of Clinical Pathology</i> , 2014, 67, 458-463.	1.0	33
55	A whole-population profile of HPV testing as a test of cure for high-grade cervical dysplasia in NSW, Australia. <i>Journal of Medical Screening</i> , 2014, 21, 151-162.	1.1	4
56	Fertility and early pregnancy outcomes after treatment for cervical intraepithelial neoplasia: systematic review and meta-analysis. <i>BMJ, The</i> , 2014, 349, g6192-g6192.	3.0	118
57	Interlaboratory Reproducibility and Proficiency Testing within the Human Papillomavirus Cervical Cancer Screening Program in Catalonia, Spain. <i>Journal of Clinical Microbiology</i> , 2014, 52, 1511-1518.	1.8	6

#	ARTICLE	IF	CITATIONS
58	Eurogin Roadmap: Comparative epidemiology of HPV infection and associated cancers of the head and neck and cervix. <i>International Journal of Cancer</i> , 2014, 134, 497-507.	2.3	164
59	Is HPV DNA testing specificity comparable to that of cytological testing in primary cervical cancer screening? Results of a meta-analysis of randomized controlled trials. <i>International Journal of Cancer</i> , 2014, 135, 166-177.	2.3	39
60	Clinical implications of (epi)genetic changes in HPV-induced cervical precancerous lesions. <i>Nature Reviews Cancer</i> , 2014, 14, 395-405.	12.8	295
61	Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis. <i>Lancet Oncology</i> , The, 2014, 15, 172-183.	5.1	508
62	HPV testing with cytology triage for cervical cancer screening in routine practice. <i>American Journal of Obstetrics and Gynecology</i> , 2014, 210, 474.e1-474.e7.	0.7	21
63	Human papillomavirus infection in women in four regions of Senegal. <i>Journal of Medical Virology</i> , 2014, 86, 248-256.	2.5	20
64	Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. <i>Lancet</i> , The, 2014, 383, 524-532.	6.3	1,282
65	Methylation marker analysis of self-sampled cervicovaginal lavage specimens to triage high-risk HPV-positive women for colposcopy. <i>International Journal of Cancer</i> , 2014, 135, 880-886.	2.3	56
66	Human papillomavirus type-specific persistence and recurrence after treatment for cervical dysplasia. <i>Journal of Medical Virology</i> , 2014, 86, 634-641.	2.5	44
68	Reply to triage of women with minor abnormal cervical cytology: Meta-analysis of the accuracy of an assay targeting messenger ribonucleic acid of 5 high-risk human papillomavirus types. <i>Cancer Cytopathology</i> , 2014, 122, 77-78.	1.4	0
69	Human papillomavirus genotype distribution in invasive cervical cancer in Bosnia and Herzegovina. <i>Cancer Epidemiology</i> , 2014, 38, 504-510.	0.8	8
70	DNA methylation analysis in self-sampled brush material as a triage test in hrHPV-positive women. <i>British Journal of Cancer</i> , 2014, 111, 1095-1101.	2.9	43
71	Protecting the underscreened women in developed countries: the value of HPV test. <i>BMC Cancer</i> , 2014, 14, 574.	1.1	15
72	Analysis of three strategies to increase screening coverage for cervical cancer in the general population of women aged 60 to 70 years: the CRICERVA study. <i>BMC Women's Health</i> , 2014, 14, 86.	0.8	15
73	Long term outcomes for women treated for cervical precancer. <i>BMJ</i> , The, 2014, 348, f7700-f7700.	3.0	29
74	Effectiveness of two strategies to follow-up ASC-US and LSIL screening results in The Netherlands using repeat cytology with or without additional hrHPV testing: a retrospective cohort study. <i>Cancer Causes and Control</i> , 2014, 25, 1141-1149.	0.8	9
75	Long term duration of protective effect for HPV negative women: follow-up of primary HPV screening randomised controlled trial. <i>BMJ</i> , The, 2014, 348, g130-g130.	3.0	103
76	Detection and Clinical Management of Cervical Pathology in the Era of HPV. <i>Current Obstetrics and Gynecology Reports</i> , 2014, 3, 107-115.	0.3	1

#	ARTICLE	IF	CITATIONS
77	Are 20 human papillomavirus types causing cervical cancer?. <i>Journal of Pathology</i> , 2014, 234, 431-435.	2.1	190
78	Embracing a new era in cervical cancer screening. <i>Lancet, The</i> , 2014, 383, 493-494.	6.3	15
79	Screening comes of age and treatment progress continues. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 77-78.	12.5	21
80	Human papillomavirus vaccination: Where are we now?. <i>Journal of Paediatrics and Child Health</i> , 2014, 50, 959-965.	0.4	20
81	European Code against Cancer, 4th Edition: Cancer screening. <i>Cancer Epidemiology</i> , 2015, 39, S139-S152.	0.8	64
83	Serial type-specific human papillomavirus (<scp>HPV</scp>) load measurement allows differentiation between regressing cervical lesions and serial virion productive transient infections. <i>Cancer Medicine</i> , 2015, 4, 1294-1302.	1.3	49
84	Human Papillomavirus Genotyping to Predict the Risk of Cervical Precancerous Lesions or Cancer in Women with Minor Abnormal Cytology in China. <i>Acta Cytologica</i> , 2015, 59, 405-411.	0.7	11
85	Beware of Kinked Frontiers: A Systematic Review of the Choice of Comparator Strategies in Cost-Effectiveness Analyses of Human Papillomavirus Testing in Cervical Screening. <i>Value in Health</i> , 2015, 18, 1138-1151.	0.1	17
86	Primary cervical cancer screening. <i>Cirurgiã Y Cirujanos (English Edition)</i> , 2015, 83, 448-453.	0.0	1
87	Human Papillomavirus (HPV) Testing for Secondary Prevention of Cervical Cancer. <i>Current Obstetrics and Gynecology Reports</i> , 2015, 4, 201-212.	0.3	4
88	Factors that influence persistence or recurrence of high-grade squamous intraepithelial lesion with positive margins after the loop electrosurgical excision procedure: a retrospective study. <i>BMC Cancer</i> , 2015, 15, 744.	1.1	29
89	Fertility and early pregnancy outcomes after conservative treatment for cervical intraepithelial neoplasia. <i>The Cochrane Library</i> , 2016, 2016, CD008478.	1.5	36
90	Comparison of the Roche cobas® 4800 and Digene Hybrid Capture® 2 HPV tests for primary cervical cancer screening in the HPV FOCAL trial. <i>BMC Cancer</i> , 2015, 15, 968.	1.1	38
91	HPV16/18 genotyping for the triage of HPV positive women in primary cervical cancer screening in Chile. <i>Infectious Agents and Cancer</i> , 2015, 10, 43.	1.2	16
92	Cost-Effectiveness of High-Risk Human Papillomavirus Testing With Messenger RNA Versus DNA Under United States Guidelines for Cervical Cancer Screening. <i>Journal of Lower Genital Tract Disease</i> , 2015, 19, 333-339.	0.9	5
93	Implementation of <scp>HPV</scp>-testing for cervical cancer screening in programmatic contexts: The <scp>J</scp>ujuy demonstration project in <scp>A</scp>rgentina. <i>International Journal of Cancer</i> , 2015, 137, 1709-1718.	2.3	36
94	Clinical performance of multiplex high-risk e6 mRNA expression in comparison with HPV DNA subtypes for the identification of women at risk of cervical cancer. <i>Journal of Medical Virology</i> , 2015, 87, 1404-1412.	2.5	0
95	The human papillomavirus Test of Cure: A lesson on compliance with the NHMRC guidelines on screening to prevent cervical cancer. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2015, 55, 185-190.	0.4	3

#	ARTICLE	IF	CITATIONS
96	Screening of cervical cancer in Catalonia 2006â€“2012. <i>Ecancermedalscience</i> , 2015, 9, 532.	0.6	7
97	Population-Level Scale-Up of Cervical Cancer Prevention Services in a Low-Resource Setting: Development, Implementation, and Evaluation of the Cervical Cancer Prevention Program in Zambia. <i>PLoS ONE</i> , 2015, 10, e0122169.	1.1	113
98	Primary Screening for Cervical Cancer Based on High-Risk Human Papillomavirus (HPV) Detection and HPV 16 and HPV 18 Genotyping, in Comparison to Cytology. <i>PLoS ONE</i> , 2015, 10, e0119755.	1.1	88
99	Barriers to and Facilitators of Compliance with Clinic-Based Cervical Cancer Screening: Population-Based Cohort Study of Women Aged 23-60 Years. <i>PLoS ONE</i> , 2015, 10, e0128270.	1.1	25
100	Long-Term Clinical Outcome after Treatment for High-Grade Cervical Lesions: A Retrospective Monoinstitutional Cohort Study. <i>BioMed Research International</i> , 2015, 2015, 1-8.	0.9	19
101	Underscreened Women Remain Overrepresented in the Pool of Cervical Cancer Cases in Spain: A Need to Rethink the Screening Interventions. <i>BioMed Research International</i> , 2015, 2015, 1-9.	0.9	14
102	A randomized controlled trial in non-responders from Newcastle upon Tyne invited to return a self-sample for Human Papillomavirus testing versus repeat invitation for cervical screening. <i>Journal of Medical Screening</i> , 2015, 22, 28-37.	1.1	39
103	Systematic review of model-based cervical screening evaluations. <i>BMC Cancer</i> , 2015, 15, 334.	1.1	36
104	High-risk HPV detection and genotyping by APTIMA HPV using cervical samples. <i>Journal of Virological Methods</i> , 2015, 221, 95-99.	1.0	4
105	Cobas 4800 HPV detection in the cervical, vaginal and urine samples of women with high-grade CIN before and after treatment. <i>Journal of Clinical Pathology</i> , 2015, 68, 567-570.	1.0	27
106	Towards cervical cancer eradication: joint force of HPV vaccination and HPV-based cervical cancer screening. <i>Clinical Microbiology and Infection</i> , 2015, 21, 806-807.	2.8	7
107	Offering Self-Sampling to Non-Attendees of Organized Primary HPV Screening: When Do Harms Outweigh the Benefits?. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 773-782.	1.1	42
108	Using Decision-Analytic Modeling to Isolate Interventions That Are Feasible, Efficient and Optimal: An Application from the Norwegian Cervical Cancer Screening Program. <i>Value in Health</i> , 2015, 18, 1088-1097.	0.1	8
109	Primary cervical cancer screening with human papillomavirus: End of study results from the ATHENA study using HPV as the first-line screening test. <i>Gynecologic Oncology</i> , 2015, 136, 189-197.	0.6	442
110	Self-sampling to increase participation in cervical cancer screening: an RCT comparing home mailing, distribution in pharmacies, and recall letter. <i>British Journal of Cancer</i> , 2015, 112, 667-675.	2.9	70
111	Para-aortic nodal metastases in cervical cancer: a blind spot in the International Federation of Gynecology and Obstetrics staging system: current diagnosis and management. <i>Future Oncology</i> , 2015, 11, 309-322.	1.1	16
112	Informed Cytology for Triaging HPV-Positive Women: Substudy Nested in the NTCC Randomized Controlled Trial. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	3.0	61
113	Triaging <sc>HPV</sc>â€“positive women with normal cytology by p16/<sc>K</sc>â€“67 dualâ€“stained cytology testing: Baseline and longitudinal data. <i>International Journal of Cancer</i> , 2015, 136, 2361-2368.	2.3	61

#	ARTICLE	IF	CITATIONS
114	Dysregulation of microRNA Expression in Human Cervical Preneoplastic and Neoplastic Lesions. <i>Pathology and Oncology Research</i> , 2015, 21, 503-508.	0.9	7
115	Offering Self-Sampling Kits for HPV Testing to Reach Women Who Do Not Attend in the Regular Cervical Cancer Screening Program. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 769-772.	1.1	100
118	Publisher's note. <i>Journal of Virological Methods</i> , 2015, 213, i.	1.0	1
119	Head-to-Head Comparison of the RNA-Based Aptima Human Papillomavirus (HPV) Assay and the DNA-Based Hybrid Capture 2 HPV Test in a Routine Screening Population of Women Aged 30 to 60 Years in Germany. <i>Journal of Clinical Microbiology</i> , 2015, 53, 2509-2516.	1.8	73
120	Results of delayed triage by HPV testing and cytology in the Norwegian Cervical Cancer Screening Programme. <i>Acta Oncologica</i> , 2015, 54, 200-209.	0.8	10
121	European guidelines for quality assurance in cervical cancer screening. Summary of the supplements on HPV screening and vaccination. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2015, 1, 22-31.	4.5	181
122	A prospective double-blind cross-sectional study of the accuracy of the use of dry vaginal tampons for self-sampling of human papillomaviruses. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2015, 122, 388-394.	1.1	5
124	HPV testing as a screen for cervical cancer. <i>BMJ, The</i> , 2015, 350, h2372-h2372.	3.0	160
125	The clinical impact of using p16 INK4a immunochemistry in cervical histopathology and cytology: An update of recent developments. <i>International Journal of Cancer</i> , 2015, 136, 2741-2751.	2.3	84
126	El cribado del c�ncer de cuello de �tero en el Sistema P�blico de Salud de Catalu�a. Evaluaci�n y seguimiento durante el periodo 2006-2012. <i>Progresos En Obstetricia Y Ginecologia</i> , 2015, 58, 209-220.	0.0	2
127	The Value of HPV-HR DNA Testing During the Follow-Up After Treatment of CIN3/AIS. <i>Pathology and Oncology Research</i> , 2015, 21, 613-617.	0.9	0
128	The Next Steps in Cervical Screening. <i>Women's Health</i> , 2015, 11, 201-212.	0.7	11
129	Which high-risk HPV assays fulfil criteria for use in primary cervical cancer screening?. <i>Clinical Microbiology and Infection</i> , 2015, 21, 817-826.	2.8	234
130	The end of the decline in cervical cancer mortality in Spain: trends across the period 1981�2012. <i>BMC Cancer</i> , 2015, 15, 287.	1.1	11
131	The implementation of an organised cervical screening programme in Poland: an analysis of the adherence to European guidelines. <i>BMC Cancer</i> , 2015, 15, 279.	1.1	27
132	The original SPF10 LiPA25 algorithm is more sensitive and suitable for epidemiologic HPV research than the SPF10 INNO-LiPA Extra. <i>Journal of Virological Methods</i> , 2015, 215-216, 22-29.	1.0	32
133	Five-Year Cervical (Pre)Cancer Risk of Women Screened by HPV and Cytology Testing. <i>Cancer Prevention Research</i> , 2015, 8, 502-508.	0.7	24
135	Epidemiology and Burden of Disease Associated with HPV Infection. <i>Current Obstetrics and Gynecology Reports</i> , 2015, 4, 181-188.	0.3	4



#	ARTICLE	IF	CITATIONS
136	Clinical and Analytical Performance of the Onclarity HPV Assay Using the VALGENT Framework. <i>Journal of Clinical Microbiology</i> , 2015, 53, 3272-3279.	1.8	50
137	Retrospective Rescreening of Negative Cervical Cytology Samples Preceding Histologically Proven CIN2-3 and Squamous Cell Carcinoma: An Educational Opportunity to Understand and Prevent Laboratory Errors. <i>Acta Cytologica</i> , 2015, 59, 265-272.	0.7	5
138	Reaching women who do not participate in the regular cervical cancer screening programme by offering self-sampling kits: A systematic review and meta-analysis of randomised trials. <i>European Journal of Cancer</i> , 2015, 51, 2375-2385.	1.3	220
139	High prevalence of abnormal cervical smears in a hospital cohort of French women beyond the upper age limit screening program. <i>Preventive Medicine</i> , 2015, 81, 157-162.	1.6	2
140	<sc>HPV</sc>16 genotype, p16/Ki67 dual staining and koilocytic morphology as potential predictors of the clinical outcome for cervical low-grade squamous intraepithelial lesions. <i>Cytopathology</i> , 2015, 26, 10-18.	0.4	20
141	Human papillomavirus vaccines: key factors in planning cost-effective vaccination programs. <i>Expert Review of Vaccines</i> , 2015, 14, 119-133.	2.0	11
142	Influences on human papillomavirus (HPV)-related information needs among women having HPV tests for follow-up of abnormal cervical cytology. <i>Journal of Family Planning and Reproductive Health Care</i> , 2015, 41, 134-141.	0.9	18
143	Clinical significance of human papillomavirus genotyping. <i>Journal of Gynecologic Oncology</i> , 2016, 27, e21.	1.0	79
144	Performance of the Cellslide <sup>®</sup> ; automated liquid-based cytology system amongst HIV-positive women. <i>African Journal of Laboratory Medicine</i> , 2016, 5, 278.	0.2	3
145	Human Papillomavirus Genotype Distribution in Invasive Cervical Cancer in Pakistan. <i>Cancers</i> , 2016, 8, 72.	1.7	16
146	Management of HPV-Related Cervical Disease: Role of p16INK4a Immunocytochemistry. <i>Review of the Literature. Tumori</i> , 2016, 102, 450-458.	0.6	10
147	HPV Testing of Biobanked Liquid-Based Cytology – a Validation Study. <i>International Journal of Biological Markers</i> , 2016, 31, 218-223.	0.7	5
148	Global strategies for cervical cancer prevention. <i>Current Opinion in Obstetrics and Gynecology</i> , 2016, 28, 4-10.	0.9	111
149	<sc>H</sc>igh-risk HPV testing in the management of atypical glandular cells: A systematic review and meta-analysis. <i>International Journal of Cancer</i> , 2016, 138, 303-310.	2.3	35
150	Cervical cancer prevention and screening: the role of human papillomavirus testing. <i>The Obstetrician and Gynaecologist</i> , 2016, 18, 251-263.	0.2	20
151	Reply to HPV test results provide useful risk stratification information in women with ASC-H Pap test findings. <i>Cancer Cytopathology</i> , 2016, 124, 754-755.	1.4	0
152	Human papillomavirus mRNA and DNA testing in women with atypical squamous cells of undetermined significance: A prospective cohort study. <i>International Journal of Cancer</i> , 2016, 139, 1839-1850.	2.3	3
153	Direct comparison of two vaginal self-sampling devices for the detection of human papillomavirus infections. <i>Journal of Clinical Virology</i> , 2016, 82, 46-50.	1.6	41

#	ARTICLE	IF	CITATIONS
154	Cervical Cancer Screening in the United States—Affiliated Pacific Islands. <i>Journal of Lower Genital Tract Disease</i> , 2016, 20, 97-104.	0.9	4
155	Triage of <sc>ASC</sc>: A meta-analysis of the accuracy of high-risk <sc>HPV</sc> testing and other markers to detect cervical precancer. <i>Cancer Cytopathology</i> , 2016, 124, 261-272.	1.4	25
156	Can the careHPV test performed in mobile units replace cytology for screening in rural and remote areas?. <i>Cancer Cytopathology</i> , 2016, 124, 581-588.	1.4	17
157	Carcinogenic human papillomavirus infection. <i>Nature Reviews Disease Primers</i> , 2016, 2, 16086.	18.1	615
159	mTOR downstream effectors, 4EBP1 and eIF4E, are overexpressed and associated with HPV status in precancerous lesions and carcinomas of the uterine cervix. <i>Oncology Letters</i> , 2016, 12, 3234-3240.	0.8	13
160	Clinical validation of hrHPV testing on vaginal and urine self-samples in primary cervical screening (cross-sectional results from the Papillomavirus Dumfries and Galloway—PaVDaG study). <i>BMJ Open</i> , 2016, 6, e010660.	0.8	64
161	Analytical performance evaluation of Anyplex II HPV28 and Euroarray HPV for genotyping of cervical samples. <i>Diagnostic Microbiology and Infectious Disease</i> , 2016, 85, 318-322.	0.8	25
162	Clinical sensitivity of HPV assays for the detection of high grade cervical disease in cervical samples treated with glacial acetic acid. <i>Journal of Clinical Virology</i> , 2016, 79, 32-35.	1.6	1
163	Clinical and analytical performance of the PapilloCheck HPV-Screening assay using the VALGENT framework. <i>Journal of Clinical Virology</i> , 2016, 81, 6-11.	1.6	25
164	Clinical and analytical performance of the BD Onclarity—HPV assay for detection of CIN2+ lesions on SurePath samples. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2016, 2, 31-37.	4.5	28
165	National- and state-level impact and cost-effectiveness of nonavalent HPV vaccination in the United States. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 5107-5112.	3.3	46
166	Discovery of new methylation markers to improve screening for cervical intraepithelial neoplasia grade 2/3. <i>Clinical Epigenetics</i> , 2016, 8, 29.	1.8	53
167	Screening women for cervical cancer carcinoma with a HPV mRNA test: first results from the Venice pilot program. <i>British Journal of Cancer</i> , 2016, 115, 525-532.	2.9	14
168	Pathophysiological basis of human papillomavirus in penile cancer: Key to prevention and delivery of more effective therapies. <i>Ca-A Cancer Journal for Clinicians</i> , 2016, 66, 481-495.	157.7	55
169	Cervical intraepithelial neoplasia: screening and management. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2016, 77, C118-C123.	0.2	16
170	HPV infection and p16 promoter methylation as predictors of ASC—US/LSIL progression. <i>Cancer Cytopathology</i> , 2016, 124, 58-65.	1.4	11
171	Evaluating HPV—negative CIN2+ in the ATHENA trial. <i>International Journal of Cancer</i> , 2016, 138, 2932-2939.	2.3	43
172	Management of high-risk HPV-positive women for detection of cervical (pre)cancer. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 961-974.	1.5	45

#	ARTICLE	IF	CITATIONS
173	Performance of a Cartridge-Based Assay for Detection of Clinically Significant Human Papillomavirus (HPV) Infection: Lessons from VALGENT (Validation of HPV Genotyping Tests). <i>Journal of Clinical Microbiology</i> , 2016, 54, 2337-2342.	1.8	48
174	Follow up with <scp>HPV</scp> test and cytology as test of cure, 6 months after conization, is reliable. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2016, 95, 1251-1257.	1.3	21
175	Human papillomavirus testing versus cytology in primary cervical cancer screening: End-of-study and extended follow-up results from the Canadian cervical cancer screening trial. <i>International Journal of Cancer</i> , 2016, 139, 2456-2466.	2.3	54
176	Cost-effective management of women with minor cervical lesions: Revisiting the application of HPV DNA testing. <i>Gynecologic Oncology</i> , 2016, 143, 326-333.	0.6	18
177	Triage of high-risk HPV positive women in cervical cancer screening. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 1073-1085.	1.1	38
178	Disease detection and resource use in the safety and control arms of the HPV FOCAL cervical cancer screening trial. <i>British Journal of Cancer</i> , 2016, 115, 1487-1494.	2.9	10
179	Systematic Comparison of Different Meta-analyses, Systematic Reviews and HTA Reports on Cervical Cancer Screening based on Cytology or HPV Test. <i>Geburtshilfe Und Frauenheilkunde</i> , 2016, 76, 1081-1085.	0.8	5
180	Impact of variations in triage cytology interpretation on human papillomavirus-based cervical screening and implications for screening algorithms. <i>European Journal of Cancer</i> , 2016, 68, 148-155.	1.3	37
181	Safety of extending screening intervals beyond five years in cervical screening programmes with testing for high risk human papillomavirus: 14 year follow-up of population based randomised cohort in the Netherlands. <i>BMJ, The</i> , 2016, 355, i4924.	3.0	86
182	Quality assurance of human papillomavirus (HPV) testing in the implementation of HPV primary screening in Norway: an inter-laboratory reproducibility study. <i>BMC Infectious Diseases</i> , 2016, 16, 698.	1.3	10
183	5-type HPV mRNA versus 14-type HPV DNA test: test performance, over-diagnosis and overtreatment in triage of women with minor cervical lesions. <i>BMC Clinical Pathology</i> , 2016, 16, 9.	1.8	14
184	Comparing SurePath, ThinPrep, and conventional cytology as primary test method: SurePath is associated with increased CIN II+ detection rates. <i>Cancer Causes and Control</i> , 2016, 27, 15-25.	0.8	44
185	HPV Genotyping from the high risk mRNA Aptima assay- a direct approach using DNA from Aptima sample tubes. <i>Journal of Virological Methods</i> , 2016, 235, 80-84.	1.0	3
186	Racial and ethnic disparities in human papillomavirus-associated cancer burden with first-generation and second-generation human papillomavirus vaccines. <i>Cancer</i> , 2016, 122, 2057-2066.	2.0	38
187	Barriers and Facilitators to Cervical Cancer Screening Among Women in Rural Ontario, Canada: The Role of Self-Collected HPV Testing. <i>Journal of Rural Health</i> , 2016, 32, 136-145.	1.6	35
188	Commercially available molecular tests for human papillomaviruses (HPV): 2015 update. <i>Journal of Clinical Virology</i> , 2016, 76, S3-S13.	1.6	105
189	World Health Organization Guidelines for treatment of cervical intraepithelial neoplasia 2-3 and screen-and-treat strategies to prevent cervical cancer. <i>International Journal of Gynecology and Obstetrics</i> , 2016, 132, 252-258.	1.0	134
190	Triage of HPV positive women in cervical cancer screening. <i>Journal of Clinical Virology</i> , 2016, 76, S49-S55.	1.6	236

#	ARTICLE	IF	CITATIONS
191	Three-year longitudinal data on the clinical performance of the Abbott RealTime High Risk HPV test in a cervical cancer screening setting. <i>Journal of Clinical Virology</i> , 2016, 76, S29-S39.	1.6	18
192	Cervical cancer screening of HPV vaccinated populations: Cytology, molecular testing, both or none. <i>Journal of Clinical Virology</i> , 2016, 76, S62-S68.	1.6	72
193	Progression of HPV infection to detectable cervical lesions or clearance in adult women: Analysis of the control arm of the VIVIANE study. <i>International Journal of Cancer</i> , 2016, 138, 2428-2438.	2.3	80
194	Detection of high-risk human papillomavirus using menstrual blood in women with high-grade squamous intraepithelial lesions or high-risk human papillomavirus infections: A pilot study. <i>Journal of Obstetrics and Gynaecology Research</i> , 2016, 42, 319-324.	0.6	3
195	Why follow-back studies should be interpreted cautiously: The case of an HPV-negative cervical lesion. <i>Cancer Cytopathology</i> , 2016, 124, 66-67.	1.4	10
196	Randomized Intervention of Self-Collected Sampling for Human Papillomavirus Testing in Under-Screened Rural Women: Uptake of Screening and Acceptability. <i>Journal of Women's Health</i> , 2016, 25, 489-497.	1.5	41
197	Xpert human papillomavirus test is a promising cervical cancer screening test for HIV-seropositive women. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2016, 2, 56-60.	4.5	19
198	Laboratory audit as part of the quality assessment of a primary HPV-screening program. <i>Journal of Clinical Virology</i> , 2016, 75, 33-36.	1.6	17
199	Vaginal Intraepithelial Neoplasia. , 2016, , 205-221.		0
200	Precancerous Lesions of Squamous Cell Carcinoma of the Cervix: Squamous Dysplasia. , 2016, , 267-284.		0
201	HPV testing in the context of post-treatment follow up (test of cure). <i>Journal of Clinical Virology</i> , 2016, 76, S56-S61.	1.6	43
202	A review of the clinical performance of the Aptima HPV assay. <i>Journal of Clinical Virology</i> , 2016, 76, S40-S48.	1.6	73
203	HPV-FASTER: broadening the scope for prevention of HPV-related cancer. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 119-132.	12.5	154
204	VALGENT: A protocol for clinical validation of human papillomavirus assays. <i>Journal of Clinical Virology</i> , 2016, 76, S14-S21.	1.6	123
205	Comparison of Xpert <sup>®</sup> HPV and Hybrid Capture <sup>®</sup> 2 DNA Test <sup>®</sup> for detection of high-risk HPV infection in cervical atypical squamous cells of undetermined significance. <i>Journal of Infection and Public Health</i> , 2017, 10, 219-223.	1.9	7
206	Primary HPV testing: a proposal for co-testing in initial rounds of screening to optimise sensitivity of cervical cancer screening. <i>Cytopathology</i> , 2017, 28, 9-15.	0.4	13
207	Serial measurement of type-specific human papillomavirus load enables classification of cervical intraepithelial neoplasia lesions according to occurring human papillomavirus-induced pathway. <i>European Journal of Cancer Prevention</i> , 2017, 26, 156-164.	0.6	14
208	Comparison of Triage Strategies for HPV-Positive Women: Canadian Cervical Cancer Screening Trial Results. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 923-929.	1.1	21

#	ARTICLE	IF	CITATIONS
209	Aptima HPV Assay versus Hybrid Capture <sup>®</sup> 2 HPV test for primary cervical cancer screening in the HPV FOCAL trial. <i>Journal of Clinical Virology</i> , 2017, 87, 23-29.	1.6	33
210	Efficacy of self-sampling in promoting participation to cervical cancer screening also in subsequent round. <i>Preventive Medicine Reports</i> , 2017, 5, 166-168.	0.8	13
211	Comparative accuracy of Pap smear and HPV screening in Ubon Ratchathani in Thailand. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2017, 3, 30-35.	4.5	16
212	HPV-based strategy in follow-up of patients treated for high-grade cervical intra-epithelial neoplasia: 5-year results in a public health surveillance setting. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2017, 210, 236-241.	0.5	12
213	Immediate referral to colposcopy versus cytological surveillance for minor cervical cytological abnormalities in the absence of HPV test. <i>The Cochrane Library</i> , 2017, 1, CD009836.	1.5	13
214	Cervical cancer incidence after screening with HPV, cytology, and visual methods: 18-year follow-up of the Guanacaste cohort. <i>International Journal of Cancer</i> , 2017, 140, 1926-1934.	2.3	10
215	A 3-year interval is too short for re-screening women testing negative for human papillomavirus: a population-based cohort study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2017, 124, 1585-1593.	1.1	16
216	Molecular tests potentially improving HPV screening and genotyping for cervical cancer prevention. <i>Expert Review of Molecular Diagnostics</i> , 2017, 17, 379-391.	1.5	55
217	The time is now to implement HPV testing for primary screening in low resource settings. <i>Preventive Medicine</i> , 2017, 98, 42-44.	1.6	28
218	The acceptability of self-sampled screening for HPV DNA: a systematic review and meta-analysis. <i>Sexually Transmitted Infections</i> , 2017, 93, 56-61.	0.8	165
219	Introduction of liquid-based cytology and human papillomavirus testing in cervical cancer screening in Luxembourg. <i>Diagnostic Cytopathology</i> , 2017, 45, 384-390.	0.5	9
220	The clinical implementation of primary <scp>HPV</scp> screening. <i>International Journal of Gynecology and Obstetrics</i> , 2017, 136, 266-271.	1.0	5
221	Self-sampling to improve cervical cancer screening coverage in Switzerland: a randomised controlled trial. <i>British Journal of Cancer</i> , 2017, 116, 1382-1388.	2.9	18
222	Human papillomavirus (HPV) E6/E7 mRNA detection in cervical exfoliated cells: a potential triage for HPV-positive women. <i>Journal of Zhejiang University: Science B</i> , 2017, 18, 256-262.	1.3	14
223	Primary HPV testing verification: A retrospective ad hoc analysis of screening algorithms on women doubly tested for cytology and HPV. <i>Diagnostic Cytopathology</i> , 2017, 45, 580-586.	0.5	9
224	Increased methylation of human papillomavirus type 16 DNA is associated with the severity of cervical lesions in infected females from northeast China. <i>Oncology Letters</i> , 2017, 13, 3809-3816.	0.8	3
225	Randomised healthcare policy evaluation of organised primary human papillomavirus screening of women aged 56-60. <i>BMJ Open</i> , 2017, 7, e014788.	0.8	23
226	High-risk human papillomavirus detection in self-sampling compared to physician-taken smear in a responder population of the Dutch cervical screening: Results of the VERA study. <i>Preventive Medicine</i> , 2017, 101, 96-101.	1.6	71

#	ARTICLE	IF	CITATIONS
227	Cervical Cancer Screening of Adolescents Should Not Be Encouraged. <i>Journal of Lower Genital Tract Disease</i> , 2017, 21, 21-25.	0.9	3
228	HPV-based cervical cancer screening- facts, fiction, and misperceptions. <i>Preventive Medicine</i> , 2017, 98, 33-35.	1.6	43
229	Eurogin 2016 Roadmap: how HPV knowledge is changing screening practice. <i>International Journal of Cancer</i> , 2017, 140, 2192-2200.	2.3	83
230	Factors related to interobserver reproducibility of conventional Pap smear cytology: a multilevel analysis of smear and laboratory characteristics. <i>Cytopathology</i> , 2017, 28, 192-202.	0.4	10
231	Stability Study of Cervical Specimens Collected by Swab and Stored Dry Followed by Human Papillomavirus DNA Detection Using the cobas 4800 Test. <i>Journal of Clinical Microbiology</i> , 2017, 55, 568-573.	1.8	14
232	Evaluation of the Clinical Performance of the HPV-Risk Assay Using the VALGENT-3 Panel. <i>Journal of Clinical Microbiology</i> , 2017, 55, 3544-3551.	1.8	30
233	RNA-Seq Analysis of Differentiated Keratinocytes Reveals a Massive Response to Late Events during Human Papillomavirus 16 Infection, Including Loss of Epithelial Barrier Function. <i>Journal of Virology</i> , 2017, 91, .	1.5	47
234	A Strategy to Find Suitable Reference Genes for miRNA Quantitative PCR Analysis and Its Application to Cervical Specimens. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 625-637.	1.2	21
236	Defining Optimal Triage Strategies for hrHPV Screenâ€‘Positive Womenâ€‘An Evaluation of HPV 16/18 Genotyping, Cytology, and p16/Ki-67 Cytoimmunochemistry. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 1629-1635.	1.1	36
237	HPV-positive women with normal cytology remain at increased risk of CIN3 after a negative repeat HPV test. <i>British Journal of Cancer</i> , 2017, 117, 1557-1561.	2.9	28
238	Cervical cancer in <sc>Africa</sc>, <sc>Latin America</sc> and the <sc>Caribbean</sc> and <sc>Asia</sc>: Regional inequalities and changing trends. <i>International Journal of Cancer</i> , 2017, 141, 1997-2001.	2.3	114
239	Comparison of the analytical and clinical performance of five tests for the detection of human papillomavirus genital infection. <i>Journal of Virological Methods</i> , 2017, 248, 238-243.	1.0	9
240	Digital droplet PCR (ddPCR) for the detection and quantification of HPV 16, 18, 33 and 45â€‘ a short report. <i>Cellular Oncology (Dordrecht)</i> , 2017, 40, 521-527.	2.1	41
241	Cytology versus HPV testing for cervical cancer screening in the general population. <i>The Cochrane Library</i> , 2017, 8, CD008587.	1.5	189
242	A systematic review and meta-analysis of studies evaluating the performance of point-of-care tests for human papillomavirus screening. <i>Sexually Transmitted Infections</i> , 2017, 93, S36-S45.	0.8	31
243	Effect of Cervical Cancer Screening Programs on Preterm Birth. <i>Obstetrics and Gynecology</i> , 2017, 130, 1207-1217.	1.2	3
244	Acceptability and feasibility of a community based participatory research project comparing cytology and urine HPV DNA testing for cervical cancer screening in Yap, Federated States of Micronesia. <i>Cancer Epidemiology</i> , 2017, 50, 283-288.	0.8	18
245	Incomplete excision of cervical precancer as a predictor of treatment failure: a systematic review and meta-analysis. <i>Lancet Oncology</i> , The, 2017, 18, 1665-1679.	5.1	207

#	ARTICLE	IF	CITATIONS
246	First-void urine: A potential biomarker source for triage of high-risk human papillomavirus infected women. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2017, 216, 1-11.	0.5	27
247	Selection of women at risk for cervical cancer in an HIV-infected South African population. <i>Aids</i> , 2017, 31, 1945-1953.	1.0	17
248	Secondary Prevention of Cervical Cancer: ASCO Resource-Stratified Clinical Practice Guideline. <i>Journal of Global Oncology</i> , 2017, 3, 635-657.	0.5	121
249	Performance of mRNA and DNA-based high-risk human papillomavirus assays in detection of high-grade cervical lesions. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2017, 96, 61-68.	1.3	11
250	Genotyping for Human Papillomavirus Types 16 and 18 in Women With Minor Cervical Lesions. <i>Annals of Internal Medicine</i> , 2017, 166, 118.	2.0	53
251	Cervical human papilloma virus (HPV) DNA primary screening test: Results of a population-based screening programme in central Italy. <i>Journal of Medical Screening</i> , 2017, 24, 153-162.	1.1	19
252	Immediate referral to colposcopy versus cytological surveillance for low-grade cervical cytological abnormalities in the absence of HPV test: A systematic review and a meta-analysis of the literature. <i>International Journal of Cancer</i> , 2017, 140, 216-223.	2.3	21
253	Good performance of p16/ki67 dual-stained cytology for surveillance of women treated for high-grade CIN. <i>International Journal of Cancer</i> , 2017, 140, 423-430.	2.3	16
254	Piperine (PP) enhanced mitomycin-C (MMC) therapy of human cervical cancer through suppressing Bcl-2 signaling pathway via inactivating STAT3/NF- $\kappa$ B. <i>Biomedicine and Pharmacotherapy</i> , 2017, 96, 1403-1410.	2.5	41
255	Analytic and Diagnostic Performances of Human Papillomavirus E6/E7 mRNA Test on up-to 11-Year-Old Liquid-Based Cervical Samples. A Biobank-Based Longitudinal Study. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1480.	1.8	9
256	Serum Immune Profiling for Early Detection of Cervical Disease. <i>Theranostics</i> , 2017, 7, 3814-3823.	4.6	17
257	Accuracy of self-collected vaginal dry swabs using the Xpert human papillomavirus assay. <i>PLoS ONE</i> , 2017, 12, e0181905.	1.1	11
258	Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial. <i>PLoS Medicine</i> , 2017, 14, e1002388.	3.9	67
259	Cervical cancer incidence after normal cytological sample in routine screening using SurePath, ThinPrep, and conventional cytology: population based study. <i>BMJ: British Medical Journal</i> , 2017, 356, j504.	2.4	24
260	Immediate biopsy of cervical cytology-negative and non-HPV16/18 oncogenic types positive patients. <i>Diagnostic Cytopathology</i> , 2018, 46, 326-330.	0.5	6
261	Validation of a new HPV self-sampling device for cervical cancer screening: The Cervical and Self-Sample In Screening (CASSIS) study. <i>Gynecologic Oncology</i> , 2018, 149, 491-497.	0.6	14
262	Cervical cancer risk in HPV-positive women after a negative FAM19A4/mir124 methylation test: A post hoc analysis in the POBASCAM trial with 14 year follow-up. <i>International Journal of Cancer</i> , 2018, 143, 1541-1548.	2.3	63
263	Human papilloma virus genotyping for the cross-sectional and longitudinal probability of developing cervical intraepithelial neoplasia grade 2 or more. <i>International Journal of Cancer</i> , 2018, 143, 333-342.	2.3	16

#	ARTICLE	IF	CITATIONS
264	<sc>HPV</sc>â€testing versus <sc>HPV</sc>â€cytology coâ€testing to predict the outcome after conization. Acta Obstetrica Et Gynecologica Scandinavica, 2018, 97, 758-765.	1.3	15
265	Self-sampling with HPV mRNA analyses from vagina and urine compared with cervical samples. Journal of Clinical Virology, 2018, 101, 69-73.	1.6	38
266	Low recurrence rate of high-grade cervical intraepithelial neoplasia after successful excision and routine colposcopy during follow-up. Medicine (United States), 2018, 97, e9719.	0.4	19
267	Human papillomavirus genotype and viral load agreement between paired first-void urine and clinician-collected cervical samples. European Journal of Clinical Microbiology and Infectious Diseases, 2018, 37, 859-869.	1.3	32
268	Assessment of the Roche Linear Array HPV Genotyping Test within the VALGENT framework. Journal of Clinical Virology, 2018, 98, 37-42.	1.6	35
269	Clinical validation of REALQUALITY RQ-HPV Screen according to the international guidelines for human papillomavirus DNA test requirements for cervical screening. Virology Journal, 2018, 15, 48.	1.4	10
270	Identifying populations most susceptible to get benefit from broadening the scope for prevention of cervical cancer: Example from Uruguay. Papillomavirus Research (Amsterdam, Netherlands), 2018, 5, 122-127.	4.5	0
271	Human papillomavirus type specific risk of progression and remission during longâ€term followâ€up of equivocal and lowâ€grade HPVâ€positive cervical smears. International Journal of Cancer, 2018, 143, 851-860.	2.3	13
272	Cervical screening in HPV-vaccinated populations. Climacteric, 2018, 21, 227-234.	1.1	8
273	ANOVA model for network meta-analysis of diagnostic test accuracy data. Statistical Methods in Medical Research, 2018, 27, 1766-1784.	0.7	63
274	Beta-binomial analysis of variance model for network meta-analysis of diagnostic test accuracy data. Statistical Methods in Medical Research, 2018, 27, 2554-2566.	0.7	15
275	Role of HPV DNA testing in modern gynaecological practice. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2018, 47, 107-118.	1.4	19
276	Secondary prevention of cervical cancer. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2018, 47, 73-85.	1.4	62
277	Initial results of population based cervical cancer screening program using HPV testing in one million <sc>T</sc>urkish women. International Journal of Cancer, 2018, 142, 1952-1958.	2.3	70
278	Is It Relevant to Keep Advocating Visual Inspection of the Cervix With Acetic Acid for Primary Cervical Cancer Screening in Limited-Resource Settings?. Journal of Global Oncology, 2018, 4, 1-5.	0.5	10
279	Preference of specimen collection methods for human papillomavirus detection for cervical cancer screening: a cross-sectional study of high-risk women in Mombasa, Kenya. Reproductive Health, 2018, 15, 206.	1.2	7
280	Cervical Cancer: Screening, Vaccination, and Preventive Strategies. , 2018, , .		0
281	Secondary Prevention of Uterine Cervical Cancer. , 2018, , .		2



#	ARTICLE	IF	CITATIONS
282	Population-based e-records to evaluate HPV triage of screen-detected atypical squamous cervical lesions in Catalonia, Spain, 2010-15. PLoS ONE, 2018, 13, e0207812.	1.1	2
283	Cervical Cancer Screening Programs in Europe: The Transition Towards HPV Vaccination and Population-Based HPV Testing. Viruses, 2018, 10, 729.	1.5	161
284	Impact of the human papillomavirus status on the development of high-grade cervical intraepithelial neoplasia in women negative for intraepithelial lesions or malignancy at the baseline: A 9-year Swedish nested case-control follow-up study. Cancer, 2018, 125, 239-248.	2.0	9
285	Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses. BMJ: British Medical Journal, 2018, 363, k4823.	2.4	437
286	Cervical Screening by Pap Test and Visual Inspection Enabling Same-Day Biopsy in Low-Resource, High-Risk Communities. Obstetrics and Gynecology, 2018, 132, 1421-1429.	1.2	8
287	Cervical cancer screening using the Cervista high-risk human papillomavirus test: opportunistic screening of a hospital-based population in Fujian province, China. Cancer Management and Research, 2018, Volume 10, 3227-3235.	0.9	7
288	Durability of clinical performance afforded by self-collected HPV testing: A 15-year cohort study in China. Gynecologic Oncology, 2018, 151, 221-228.	0.6	11
289	Evaluation of Sensitivity and Specificity of Pap Smear, LBC and HPV in Screening of Cervical Cancer. Indian Journal of Gynecologic Oncology, 2018, 16, 1.	0.1	9
290	The Valgent4 protocol: Robust analytical and clinical validation of 11 HPV assays with genotyping on cervical samples collected in SurePath medium. Journal of Clinical Virology, 2018, 108, 64-71.	1.6	37
291	Validation of intra- and inter-laboratory reproducibility of the Xpert HPV assay according to the international guidelines for cervical cancer screening. Virology Journal, 2018, 15, 166.	1.4	9
292	Clinical Evaluation of INNO-LiPA HPV Genotyping EXTRA II Assay Using the VALGENT Framework. International Journal of Molecular Sciences, 2018, 19, 2704.	1.8	23
293	Defining hrHPV genotypes in cervical intraepithelial neoplasia by laser capture microdissection supports reflex triage of self-samples using HPV16/18 and FAM19A4/miR124-2 methylation. Gynecologic Oncology, 2018, 151, 311-318.	0.6	7
294	Validation of EUROArray HPV test using the VALGENT framework. Journal of Clinical Virology, 2018, 108, 38-42.	1.6	18
295	Clinical and Analytical Evaluation of the Anyplex II HPV HR Detection Assay within the VALGENT-3 Framework. Journal of Clinical Microbiology, 2018, 56, .	1.8	20
296	Residual lesions in uterine specimens after loop electrosurgical excision procedure in patients with CIN. Archives of Gynecology and Obstetrics, 2018, 298, 805-812.	0.8	13
297	HPV screening, invasive cervical cancer and screening policy in Australia. Journal of the American Society of Cytopathology, 2018, 7, 292-299.	0.2	11
298	VALHUDES: A protocol for validation of human papillomavirus assays and collection devices for HPV testing on self-samples and urine samples. Journal of Clinical Virology, 2018, 107, 52-56.	1.6	72
299	A Head-to-Head Analytical Comparison of Cobas 4800 HPV, PapilloCheck HPV Screening, and LMNX Genotyping Kit HPV GP for Detection of Human Papillomavirus DNA in Cervical and Cervicovaginal Swabs. Journal of Molecular Diagnostics, 2018, 20, 849-858.	1.2	10

#	ARTICLE	IF	CITATIONS
300	Moving towards an organized cervical cancer screening: costs and impact. <i>European Journal of Public Health</i> , 2018, 28, 1132-1138.	0.1	6
301	Implementation Considerations Using HPV Self-Collection to Reach Women Under-Screened for Cervical Cancer in High-Income Settings. <i>Current Oncology</i> , 2018, 25, 4-7.	0.9	14
302	Human Papillomavirus Vaccines. , 2018, , 430-455.e10.		5
303	Host-cell DNA methylation patterns during high-risk HPV-induced carcinogenesis reveal a heterogeneous nature of cervical pre-cancer. <i>Epigenetics</i> , 2018, 13, 769-778.	1.3	43
304	Good concordance of HPV detection between cervico-vaginal self-samples and general practitioner-collected samples using the Cobas 4800 HPV DNA test. <i>BMC Infectious Diseases</i> , 2018, 18, 348.	1.3	33
305	Evaluating a community-based cervical cancer screening strategy in Western Kenya: a descriptive study. <i>BMC Women's Health</i> , 2018, 18, 116.	0.8	25
306	Cervical Cancer Screening: The Transformational Role of Routine Human Papillomavirus Testing. <i>Annals of Internal Medicine</i> , 2018, 168, 75.	2.0	5
307	Triage of high-risk HPV-positive women in population-based screening by miRNA expression analysis in cervical scrapes; a feasibility study. <i>Clinical Epigenetics</i> , 2018, 10, 76.	1.8	18
308	Preventing cervical cancer using HPV self-sampling: direct mailing of test-kits increases screening participation more than timely opt-in procedures - a randomized controlled trial. <i>BMC Cancer</i> , 2018, 18, 273.	1.1	55
309	Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. <i>The Cochrane Library</i> , 2020, 2020, CD009069.	1.5	288
310	Screening for Cervical Cancer in Primary Care. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 706.	3.8	112
311	Comparison between professional sampling and self-sampling for HPV-based cervical cancer screening among postmenopausal women. <i>International Journal of Gynecology and Obstetrics</i> , 2018, 142, 359-364.	1.0	8
312	Guidelines for HPV-DNA Testing for Cervical Cancer Screening in Brazil. <i>Revista Brasileira De Ginecologia E Obstetricia</i> , 2018, 40, 360-368.	0.3	22
313	Projected future impact of HPV vaccination and primary HPV screening on cervical cancer rates from 2017-2035: Example from Australia. <i>PLoS ONE</i> , 2018, 13, e0185332.	1.1	52
314	Is self-sampling to test for high-risk papillomavirus an acceptable option among women who have been treated for high-grade cervical intraepithelial neoplasia?. <i>PLoS ONE</i> , 2018, 13, e0199038.	1.1	11
315	Implementation of HPV-based Cervical Cancer Screening Combined with Self-sampling Using a Midwifery Network Across Rural Greece: The GRECOSELF Study. <i>Cancer Prevention Research</i> , 2019, 12, 701-710.	0.7	17
316	Suboptimal HIV Pre-exposure Prophylaxis Awareness and Willingness to Use Among Women Who Use Drugs in the United States: A Systematic Review and Meta-analysis. <i>AIDS and Behavior</i> , 2019, 23, 2641-2653.	1.4	21
317	Sexually transmitted infections - laboratory diagnosis. <i>Revista Da Associação Médica Brasileira</i> , 2019, 65, 745-754.	0.3	1

#	ARTICLE	IF	CITATIONS
318	Evaluation of alternately combining HPV viral load and 16/18 genotyping in secondary screening algorithms. PLoS ONE, 2019, 14, e0220200.	1.1	12
319	Factors associated with high-risk human papillomavirus infection and high-grade cervical neoplasia: A population-based study in Paraguay. PLoS ONE, 2019, 14, e0218016.	1.1	13
320	Application of p16/Ki-67 dual-staining cytology in cervical cancers. Journal of Cancer, 2019, 10, 2654-2660.	1.2	43
321	Gynecologic Cytology. , 2019, , 571-630.		1
322	Assessment of a new low-cost, PCR-based strategy for high-risk human papillomavirus DNA detection for cervical cancer prevention. BMC Infectious Diseases, 2019, 19, 842.	1.3	10
323	Clinical performance of the HPV-Risk assay on cervical samples in SurePath medium using the VALGENT-4 panel. Journal of Clinical Virology, 2019, 121, 104201.	1.6	9
324	Quality control of cervical cytology using a 3-type HPV mRNA test increases screening program sensitivity of cervical intraepithelial neoplasia grade 2+ in young Norwegian womenâ€”A cohort study. PLoS ONE, 2019, 14, e0221546.	1.1	2
325	Clinical validation of the HPVIR high-risk HPV test on cervical samples according to the international guidelines for human papillomavirus DNA test requirements for cervical cancer screening. Virology Journal, 2019, 16, 107.	1.4	18
326	Profile of MeltPro® HPV test for human papillomavirus genotyping and cervical precancer screening. Expert Review of Molecular Diagnostics, 2019, 19, 857-862.	1.5	3
327	Performance of vaginal self-sampling for human papillomavirus testing among women living with HIV in Botswana. International Journal of STD and AIDS, 2019, 30, 1169-1176.	0.5	11
328	Using the VALGENT-3 framework to assess the clinical and analytical performance of the RIATOL qPCR HPV genotyping assay. Journal of Clinical Virology, 2019, 120, 57-62.	1.6	12
329	Management and treatment of cervical intraepithelial neoplasia in the Netherlands after referral for colposcopy. Acta Obstetrica Et Gynecologica Scandinavica, 2019, 98, 737-746.	1.3	10
330	A Nationwide Study Comparing Knowledge and Beliefs about HPV among Female Students before and after HPV Vaccination. Journal of Pediatric and Adolescent Gynecology, 2019, 32, 158-164.	0.3	9
331	Experience with HPV self-sampling and clinician-based sampling in women attending routine cervical screening in the Netherlands. Preventive Medicine, 2019, 125, 5-11.	1.6	48
332	Profile of the BD HPV Onclarity™ assay. Expert Review of Molecular Diagnostics, 2019, 19, 565-570.	1.5	6
333	Routine cervical screening by primary <scp>HPV</scp> testing: early findings in the renewed National Cervical Screening Program. Medical Journal of Australia, 2019, 211, 113-119.	0.8	39
334	Menopausal status is associated with a high risk for residual disease after cervical conization with positive margins. PLoS ONE, 2019, 14, e0217562.	1.1	8
335	Self-sampling for human papillomavirus (HPV) testing: a systematic review and meta-analysis. BMJ Global Health, 2019, 4, e001351.	2.0	158

#	ARTICLE	IF	CITATIONS
336	Long-term CIN3+ risk of HPV positive women after triage with FAM19A4/miR124-2 methylation analysis. <i>Gynecologic Oncology</i> , 2019, 154, 368-373.	0.6	32
337	HPV-based screening for cervical cancer among women 55-59 years of age. <i>PLoS ONE</i> , 2019, 14, e0217108.	1.1	16
338	HPV-based cervical cancer screening, including self-sampling, versus screening with cytology in Argentina. <i>The Lancet Global Health</i> , 2019, 7, e688-e689.	2.9	9
339	Population-based primary HPV mRNA cervical screening compared with cytology screening. <i>Preventive Medicine</i> , 2019, 124, 61-66.	1.6	11
340	Programmatic human papillomavirus testing in cervical cancer prevention in the Jujuy Demonstration Project in Argentina: a population-based, before-and-after retrospective cohort study. <i>The Lancet Global Health</i> , 2019, 7, e772-e783.	2.9	56
341	Predictive Value of HPV Testing in Self-collected and Clinician-Collected Samples Compared with Cytology in Detecting High-grade Cervical Lesions. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 1134-1140.	1.1	23
342	Comparison of urine, self-collected vaginal swab, and cervical swab samples for detecting human papillomavirus (HPV) with Roche Cobas HPV, Anyplex II HPV, and RealTime HR-S HPV assay. <i>Journal of Virological Methods</i> , 2019, 269, 77-82.	1.0	25
343	Accuracy of genotyping for HPV16 and 18 to triage women with low-grade squamous intraepithelial lesions: a pooled analysis of VALGENT studies. <i>Expert Review of Molecular Diagnostics</i> , 2019, 19, 543-551.	1.5	11
344	Recurrent disease after treatment for cervical pre-cancer: determining whether prophylactic HPV vaccination could play a role in prevention of secondary lesions. <i>Climacteric</i> , 2019, 22, 596-602.	1.1	13
345	Clinical impact and cost-effectiveness of primary cytology versus human papillomavirus testing for cervical cancer screening in England. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 669-675.	1.2	16
346	PCR-reverse dot blot human papillomavirus genotyping as a primary screening test for cervical cancer in a hospital-based cohort. <i>Journal of Gynecologic Oncology</i> , 2019, 30, e29.	1.0	10
348	Role of <sc>HPV DNA</sc>, <sc> HPV mRNA</sc> and cytology in the follow-up of women treated for cervical dysplasia. <i>Apmis</i> , 2019, 127, 196-201.	0.9	5
349	Pathways to a cancer-free future: A protocol for modelled evaluations to maximize the future impact of interventions on cervical cancer in Australia. <i>Gynecologic Oncology</i> , 2019, 152, 465-471.	0.6	14
350	Complementarity between miRNA expression analysis and DNA methylation analysis in hrHPV-positive cervical scrapes for the detection of cervical disease. <i>Epigenetics</i> , 2019, 14, 558-567.	1.3	7
351	Cost-effectiveness evaluation of HPV self-testing offered to non-attendees in cervical cancer screening in Switzerland. <i>Gynecologic Oncology</i> , 2019, 153, 92-99.	0.6	16
352	Meta-analysis of the accuracy of p16 or p16/Ki67 immunocytochemistry versus HPV testing for the detection of CIN2+/CIN3+ in triage of women with minor abnormal cytology. <i>Cancer Cytopathology</i> , 2019, 127, 169-180.	1.4	31
353	The use of human papillomavirus DNA methylation in cervical intraepithelial neoplasia: A systematic review and meta-analysis. <i>EBioMedicine</i> , 2019, 50, 246-259.	2.7	31
354	Human Papillomavirus Genotyping Compared With a Qualitative High-Risk Human Papillomavirus Test After Treatment of High-Grade Cervical Intraepithelial Neoplasia. <i>Obstetrics and Gynecology</i> , 2019, 134, 452-462.	1.2	18

#	ARTICLE	IF	CITATIONS
355	Introduction of primary screening using high-risk HPV DNA detection in the Dutch cervical cancer screening programme: a population-based cohort study. <i>BMC Medicine</i> , 2019, 17, 228.	2.3	83
356	Experience of a "Screen and treat"™ program for secondary prevention of cervical cancer in Uttar Pradesh, India. <i>Journal of Obstetrics and Gynaecology Research</i> , 2019, 46, 320-327.	0.6	5
357	HPV-Associated Anal Cancer in the HIV/AIDS Patient. <i>Cancer Treatment and Research</i> , 2019, 177, 183-209.	0.2	41
358	Residual or Recurrent Precancerous Lesions After Treatment of Cervical Lesions in Human Immunodeficiency Virus-infected Women: A Systematic Review and Meta-analysis of Treatment Failure. <i>Clinical Infectious Diseases</i> , 2019, 69, 1555-1565.	2.9	35
359	Assessing the time dependence of prognostic values of cytology and human papillomavirus testing in cervical cancer screening. <i>International Journal of Cancer</i> , 2019, 144, 2408-2418.	2.3	1
360	Evaluation of a validated methylation triage signature for human papillomavirus positive women in the HPV FOCAL cervical cancer screening trial. <i>International Journal of Cancer</i> , 2019, 144, 2587-2595.	2.3	56
361	Implementation of HPV-based cervical cancer screening in an organised regional screening programme: 3 years of experience. <i>Cytopathology</i> , 2019, 30, 150-156.	0.4	15
362	Longitudinal Clinical Performance of the RNA-Based Aptima Human Papillomavirus (AHPV) Assay in Comparison to the DNA-Based Hybrid Capture 2 HPV Test in Two Consecutive Screening Rounds with a 6-Year Interval in Germany. <i>Journal of Clinical Microbiology</i> , 2019, 57, .	1.8	26
363	Role of Ancillary Techniques in Gynecologic Cytopathology Specimens. <i>Acta Cytologica</i> , 2020, 64, 63-70.	0.7	4
364	RNA-based high-risk HPV genotyping and identification of high-risk HPV transcriptional activity in cervical tissues. <i>Modern Pathology</i> , 2020, 33, 748-757.	2.9	11
365	Primary HPV-based cervical cancer screening in Europe: implementation status, challenges, and future plans. <i>Clinical Microbiology and Infection</i> , 2020, 26, 579-583.	2.8	165
366	Long-term predictors of residual or recurrent cervical intraepithelial neoplasia 3 after treatment with a large loop excision of the transformation zone: a retrospective study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2020, 127, 377-387.	1.1	33
367	Incomplete excision of cervical intraepithelial neoplasia as a predictor of the risk of recurrent disease—a 16-year follow-up study. <i>American Journal of Obstetrics and Gynecology</i> , 2020, 222, 172.e1-172.e12.	0.7	38
368	<i>FAM19A4/miR124</i> methylation in invasive cervical cancer: A retrospective cross-sectional worldwide study. <i>International Journal of Cancer</i> , 2020, 147, 1215-1221.	2.3	40
369	Disease detection at the 48-month exit round of the HPV FOCAL cervical cancer screening trial in women per protocol eligible for routine screening. <i>International Journal of Cancer</i> , 2020, 146, 1810-1818.	2.3	0
370	Triage of low-grade squamous intraepithelial lesions using human papillomavirus messenger ribonucleic acid tests—A prospective population-based register study. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2020, 99, 204-212.	1.3	3
371	Risk of CIN2 or more severe lesions after negative HPV mRNA E6/E7 overexpression assay and after negative HPV DNA test: Concurrent cohorts with a 5-year follow-up. <i>International Journal of Cancer</i> , 2020, 146, 3114-3123.	2.3	12
372	Primary HPV testing with cytology versus cytology alone in cervical screening—A prospective randomized controlled trial with two rounds of screening in a Chinese population. <i>International Journal of Cancer</i> , 2020, 147, 1152-1162.	2.3	16

#	ARTICLE	IF	CITATIONS
373	Reducing overtreatment associated with overdiagnosis in cervical cancer screening: A model-based benefit-harm analysis for Austria. <i>International Journal of Cancer</i> , 2020, 147, 1131-1142.	2.3	13
374	The Pathology of Cervical Precancer and Cancer and its importance in clinical practice. , 2020, , 85-109.		2
375	Primary Screening by Human Papillomavirus Testing: Development, Implementation, and Perspectives. , 2020, , 245-268.		0
376	Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. <i>The Lancet Global Health</i> , 2020, 8, e191-e203.	2.9	2,111
377	Histomorphologic assessment and distribution of high-risk human papillomavirus (HPV) types in cervical high-grade squamous intraepithelial lesions with unusual histomorphologic features. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 476, 251-260.	1.4	4
378	Risk prediction of cervical abnormalities: The value of sociodemographic and lifestyle factors in addition to HPV status. <i>Preventive Medicine</i> , 2020, 130, 105927.	1.6	11
379	A roadmap for a comprehensive control of cervical cancer in Poland: integration of available solutions into current practice in primary and secondary prevention. <i>European Journal of Cancer Prevention</i> , 2020, 29, 157-164.	0.6	9
380	Deep sequencing detects human papillomavirus (HPV) in cervical cancers negative for HPV by PCR. <i>British Journal of Cancer</i> , 2020, 123, 1790-1795.	2.9	36
382	Psychology and the Global Human Rights Agenda on Sexual Orientation and Gender Identity. , 2020, , 332-345.		0
383	Increased miR-20b Level in High Grade Cervical Intraepithelial Neoplasia. <i>Pathology and Oncology Research</i> , 2020, 26, 2633-2640.	0.9	7
384	Impact of HPV-16/18 AS04-adjuvanted vaccine on preventing subsequent infection and disease after excision treatment: post-hoc analysis from a randomized controlled trial. <i>BMC Infectious Diseases</i> , 2020, 20, 846.	1.3	8
385	<p>Combined Detection of ACTN4 and SCC-Ag is a Promising Serological Biomarker for Cervical Intraepithelial Neoplasia 3 or Worse: A Case-Control Study</p>. <i>Risk Management and Healthcare Policy</i> , 2020, Volume 13, 2677-2687.	1.2	2
386	Conservative management of CIN2 p16 positive lesions in women with multiple HPV infection. <i>BMC Infectious Diseases</i> , 2020, 20, 801.	1.3	4
387	Triage of hrHPV-positive women: comparison of two commercial methylation-specific PCR assays. <i>Clinical Epigenetics</i> , 2020, 12, 171.	1.8	15
388	Prophylactic HPV vaccination after conization: A systematic review and meta-analysis. <i>Vaccine</i> , 2020, 38, 6402-6409.	1.7	62
389	Selecting human papillomavirus genotypes to optimize the performance of screening tests among South African women. <i>Cancer Medicine</i> , 2020, 9, 6813-6824.	1.3	21
390	Universal cervical cancer control through a right to health lens: refocusing national policy and programmes on underserved women. <i>BMC International Health and Human Rights</i> , 2020, 20, 21.	2.5	9
391	Evaluation of the concordance in HPV type between self- and physician-collected samples using a brush-based device and a PCR-based HPV DNA test in Japanese referred patients with abnormal cytology or HPV infection. <i>International Journal of Clinical Oncology</i> , 2020, 25, 1854-1860.	1.0	21

#	ARTICLE	IF	CITATIONS
392	14-type HPV mRNA test in triage of HPV DNA-positive postmenopausal women with normal cytology. BMC Cancer, 2020, 20, 1025.	1.1	4
394	How Fear and Hope Shaped the Universal Declaration of Human Rights. , 2020, , 11-24.		1
395	Human Rights Developments from the Universal Declaration to the Present. , 2020, , 25-40.		2
396	Connecting Human Rights and Psychological Ethics in a Globalizing World. , 2020, , 41-55.		1
397	A Historical Narrative of Psychology Engaging Human Rights within the Framework of the United Nations. , 2020, , 56-72.		2
398	The Intersection of Psychology and Human Rights in Addressing Racism, Discrimination, and Xenophobia. , 2020, , 75-89.		0
399	Poverty and the Human Rights of Children and Youth through the Lenses of Psychology and Sociology. , 2020, , 90-104.		2
400	Labor Rights as Human Rights. , 2020, , 105-120.		0
401	Whose Culture? Challenging the Idea of an Opposition between Women's Human Rights and the Right to Culture. , 2020, , 121-134.		0
403	Child Rights. , 2020, , 150-163.		1
404	Human Rights of Persons with Disabilities. , 2020, , 164-180.		0
405	Mental Health and Human Rights. , 2020, , 183-196.		1
406	Cultivating Our Common Humanity. , 2020, , 197-211.		0
407	From Refugees to Immigrants. , 2020, , 212-226.		2
408	UN Convention on the Rights of the Child and the Sustainable Development Goals. , 2020, , 227-242.		2
409	The Global Contributions of Psychology to Understanding and Addressing the Non-negotiability of Human Dignity and Health Equity. , 2020, , 243-257.		1
410	Human Rights and Psychology from Indigenous Perspectives. , 2020, , 258-272.		1
412	Human Rights Seen through a Cultural Lens. , 2020, , 288-302.		1

#	ARTICLE	IF	CITATIONS
413	Human Rights and Well-Being of Older Persons. , 2020, , 303-316.		2
414	Reproductive Justice, Psychology, and Human Rights. , 2020, , 317-331.		0
415	Psychosocial Features of Movements That Have Advanced Human Rights. , 2020, , 346-360.		0
416	Principles of Care of Survivors of Organized Violence in a Global Society. , 2020, , 361-372.		0
417	Mental Health and Psychosocial Support in Humanitarian Settings. , 2020, , 373-388.		1
418	Children and Violence across the Life Span. , 2020, , 389-403.		1
419	Psychology and Human Rights in the Age of Genomics and Neuroscience. , 2020, , 404-413.		0
420	Behavioral Insights, Public Policy, and Human Rights. , 2020, , 414-427.		0
421	From Human Resources to Human Rights. , 2020, , 428-442.		6
423	Decolonization and Liberation Psychology. , 2020, , 461-474.		0
424	Education of Psychologists for Human Rights Awareness, Accountability, and Action. , 2020, , 475-489.		0
425	Conducting Psychological Research across Borders. , 2020, , 490-503.		0
426	Diversity in Psychology Education and Training. , 2020, , 504-519.		0
427	Preparing Future Generations. , 2020, , 520-534.		2
428	Human Rights and Reconciliation. , 2020, , 537-552.		3
429	The Australian Psychological Society's Apology to Aboriginal and Torres Strait Islander People. , 2020, , 553-567.		0
430	The Role of Scientific Societies in Promoting and Protecting Human Rights and the Example of the American Psychological Association. , 2020, , 568-582.		1
431	Human Rights, Psychology, and Artificial Intelligence. , 2020, , 583-590.		0



#	ARTICLE	IF	CITATIONS
432	Psychology, Human Rights, and the Implementation of the United Nationsâ€™ 2030 Agenda for Sustainable Development. , 2020, , 591-606.		0
433	Evaluation of six methylation markers derived from genome-wide screens for detection of cervical precancer and cancer. Epigenomics, 2020, 12, 1569-1578.	1.0	15
434	Reproducibility of a Rapid Human Papillomavirus Test at Different Levels of the Healthcare System in Tanzania: The AISHA Study. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 2261-2268.	1.1	3
435	Urine collection in cervical cancer screening â€“ analytical comparison of two HPV DNA assays. BMC Infectious Diseases, 2020, 20, 926.	1.3	30
436	Simultaneous Detection and Viral DNA Load Quantification of Different Human Papillomavirus Types in Clinical Specimens by the High Analytical Droplet Digital PCR Method. Frontiers in Microbiology, 2020, 11, 591452.	1.5	55
437	The application of BMRT-HPV viral load to secondary screening strategies for cervical cancer. PLoS ONE, 2020, 15, e0232117.	1.1	12
438	Use of the Aptima mRNA high-risk human papillomavirus (HR-HPV) assay compared to a DNA HR-HPV assay in the English cervical screening programme: a decision tree model based economic evaluation. BMJ Open, 2020, 10, e031303.	0.8	16
439	The effectiveness of HPV viral load, reflected by Cobas 4800 HPV-Ct values for the triage of HPV-positive women in primary cervical cancer screening: Direct endocervical samples. PLoS ONE, 2020, 15, e0232107.	1.1	8
440	Clinical validation of full genotyping CLARTÂ® HPV4S assay on SurePath and ThinPrep collected screening samples according to the international guidelines for human papillomavirus test requirements for cervical screening. BMC Cancer, 2020, 20, 396.	1.1	9
441	The Performance of Immunocytochemistry Staining as Triage Tests for High-Risk HPV-Positive Women: A 24-Month Prospective Study. Journal of Oncology, 2020, 2020, 1-8.	0.6	5
442	Cervical screening: ESGO-EFC position paper of the European Society of Gynaecologic Oncology (ESGO) and the European Federation of Colposcopy (EFC). British Journal of Cancer, 2020, 123, 510-517.	2.9	74
443	Combined use of cytology, p16 immunostaining and genotyping for triage of women positive for high-risk human papillomavirus at primary screening. International Journal of Cancer, 2020, 147, 1864-1873.	2.3	16
444	Efficacy of strategies to increase participation in cervical cancer screening: GPs offering self-sampling kits for HPV testing versus recommendations to have a pap smear taken - A randomised controlled trial. Papillomavirus Research (Amsterdam, Netherlands), 2020, 9, 100194.	4.5	9
445	Triage of HPV-positive women in Norway using cytology, HPV16/18 genotyping and HPV persistence. British Journal of Cancer, 2020, 122, 1577-1579.	2.9	21
446	2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors. Journal of Lower Genital Tract Disease, 2020, 24, 102-131.	0.9	608
447	Primary HPV screening for cervical cancer. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2020, 65, 98-108.	1.4	91
448	&lt;p&gt;Clinical Performance of Human Papillomavirus (HPV) Testing versus Cytology for Cervical Cancer Screening: Results of a Large Danish Implementation Study&lt;p&gt;. Clinical Epidemiology, 2020, Volume 12, 203-213.	1.5	18
449	High-risk Human Papillomavirus Testing for Triage of Women with Previous Cytological Abnormalities from the Vale do Ribeira Region. Revista Brasileira De Ginecologia E Obstetricia, 2020, 42, 340-348.	0.3	0

#	ARTICLE	IF	CITATIONS
450	Clinical evaluation of modifications to a human papillomavirus assay to optimise its utility for cervical cancer screening in low-resource settings: a diagnostic accuracy study. <i>The Lancet Global Health</i> , 2020, 8, e296-e304.	2.9	41
451	Assessment of clinical performance of an ultrasensitive nanowire assay for detecting human papillomavirus DNA in urine. <i>Gynecologic Oncology</i> , 2020, 156, 641-646.	0.6	7
452	Clinical and Analytical Performance of the BD Onclarity HPV Assay with SurePath Screening Samples from the Danish Cervical Screening Program Using the VALGENT Framework. <i>Journal of Clinical Microbiology</i> , 2020, 58, .	1.8	24
453	Triage options to manage high-risk human papillomavirus positive women: A population-based cross-sectional study from rural China. <i>International Journal of Cancer</i> , 2020, 147, 2053-2064.	2.3	17
454	Commercially available molecular tests for human papillomaviruses: a global overview. <i>Clinical Microbiology and Infection</i> , 2020, 26, 1144-1150.	2.8	84
455	Real-world data on cervical cancer risk stratification by cytology and HPV genotype to inform the management of HPV-positive women in routine cervical screening. <i>British Journal of Cancer</i> , 2020, 122, 1715-1723.	2.9	43
456	Evaluation of PCR-Reverse Dot Blot Human Papillomavirus Genotyping Test in Predicting Residual/Recurrent CIN 2+ in Posttreatment Patients in China. <i>Cancer Management and Research</i> , 2020, Volume 12, 2369-2379.	0.9	5
457	Analytical performance of HPV assays on vaginal self-collected vs practitioner-collected cervical samples: the SCoPE study. <i>Journal of Clinical Virology</i> , 2020, 127, 104375.	1.6	30
458	Evaluation and Optimization of the Clinical Accuracy of Hybribio's 14 High-Risk HPV with 16/18 Genotyping Assay within the VALGENT-3 Framework. <i>Journal of Clinical Microbiology</i> , 2020, 58, .	1.8	7
459	Detection of HPV mRNA in Self-collected Vaginal Samples Among Urban Ethiopian Women. <i>Anticancer Research</i> , 2020, 40, 1513-1517.	0.5	1
460	The European response to the WHO call to eliminate cervical cancer as a public health problem. <i>International Journal of Cancer</i> , 2021, 148, 277-284.	2.3	52
461	Dual staining for p16/Ki67 to detect high-grade cervical lesions: Results from the Screening Triage Ascertainig Intraepithelial Neoplasia by Immunostain Testing study. <i>International Journal of Cancer</i> , 2021, 148, 492-501.	2.3	11
462	Comparison of immediate colposcopy, repeat conventional cytology and high-risk human papillomavirus testing for the clinical management of atypical squamous cells of undetermined significance cytology in routine health services of Medellin, Colombia: The ASCUS- <i>COL</i> trial. <i>International Journal of Cancer</i> , 2021, 148, 1394-1407.	2.3	5
463	Cervical Cancer Screening: Comparison of Conventional Pap Smear Test, Liquid-Based Cytology, and Human Papillomavirus Testing as Stand-alone or Cotesting Strategies. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 474-484.	1.1	24
464	Could HPV Testing on Self-collected Samples Be Routinely Used in an Organized Cervical Screening Program? A Modeled Analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 268-277.	1.1	24
465	Health economic evaluation of primary human papillomavirus screening in urban populations in China. <i>Cancer Epidemiology</i> , 2021, 70, 101861.	0.8	5
466	Clinical relevance of partial HPV16/18 genotyping in stratifying HPV-positive women attending routine cervical cancer screening: a population-based cohort study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2021, 128, 1353-1362.	1.1	5
467	Risk of Cervical Intraepithelial Neoplasia Grade 3 or Worse in HPV-Positive Women with Normal Cytology and Five-Year Type Concordance: A Randomized Comparison. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 485-491.	1.1	0

#	ARTICLE	IF	CITATIONS
468	The optimal HPV-screening protocol in Eastern-Europe: The example of Slovenia. <i>Gynecologic Oncology</i> , 2021, 160, 118-127.	0.6	5
470	Correlation of High-Risk HPV Genotypes with Pap Test Findings: A Retrospective Study in Eastern Province, Saudi Arabia. <i>Acta Cytologica</i> , 2021, 65, 48-55.	0.7	3
471	FAM19A4/miR124-2 methylation analysis as a triage test for HPV-positive women: cross-sectional and longitudinal data from a Dutch screening cohort. <i>Clinical Microbiology and Infection</i> , 2021, 27, 125.e1-125.e6.	2.8	24
472	Use of extended HR-HPV Genotyping in improving the Triage Strategy of 2019 ASCCP recommendations in Women with positive HR-HPV diagnosis and Simultaneous LSIL Cytology Results. <i>Journal of Cancer</i> , 2021, 12, 4332-4340.	1.2	6
473	Long term results of follow-up after HPV self-sampling with devices Qvintip and HerSwab in women non-attending cervical screening programme. <i>Radiology and Oncology</i> , 2021, 55, 187-195.	0.6	4
474	Self-sampling for high-risk human papillomavirus as a follow-up alternative after treatment of high-grade cervical intraepithelial neoplasia. <i>Oncology Letters</i> , 2021, 21, 240.	0.8	3
475	Comparison of cytology and human papillomavirus-based primary testing in cervical screening programs in the Nordic countries. <i>Journal of Medical Screening</i> , 2021, 28, 464-471.	1.1	2
476	A comparison of ThinPrep against four non-volatile transport media for HPV testing at or near the point of care. <i>Pathology</i> , 2021, 53, 264-266.	0.3	6
477	Benefits and potential harms of human papillomavirus (HPV)-based cervical cancer screening: A real-world comparison of HPV testing versus cytology. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2021, 100, 394-402.	1.3	18
478	Aptima HPV messenger RNA testing and histopathologic follow-up in women with HSIL cytology: A study emphasizing additional review of HPV-negative cases. <i>Cancer Cytopathology</i> , 2021, 129, 622-631.	1.4	2
479	The treatment strategy of patients with positive margins after cervical cold knife conization: A 7-year retrospective study in China. <i>International Journal of Gynecology and Obstetrics</i> , 2022, 156, 159-165.	1.0	3
480	Clinical evaluation of p16 <sup>INK4a</sup> immunocytology in cervical cancer screening: A population-based cross-sectional study from rural China. <i>Cancer Cytopathology</i> , 2021, 129, 679-692.	1.4	2
481	Virus del papiloma humano (VPH) y cáncer. <i>Medicina Y Laboratorio</i> , 2021, 25, 467-483.	0.0	2
482	Cervical lesion assessment using real-time microendoscopy image analysis in Brazil: The CLARA study. <i>International Journal of Cancer</i> , 2021, 149, 431-441.	2.3	12
483	Determinants of Human Papillomavirus Vaccine Uptake by Adult Women Attending Cervical Cancer Screening in 9 European Countries. <i>American Journal of Preventive Medicine</i> , 2021, 60, 478-487.	1.6	13
484	Clinical and Analytical Evaluation of the Alinity m HR HPV Assay within the VALGENT-3 Framework. <i>Journal of Clinical Microbiology</i> , 2021, 59, .	1.8	6
485	DNA methylation marker for the triage of hrHPV positive women in cervical cancer screening: Real-world evidence in Taiwan. <i>Gynecologic Oncology</i> , 2021, 161, 429-435.	0.6	17
486	Additional diagnostic capabilities in the practice of a PAP-test using liquid-based cytology. <i>Journal of Clinical Practice</i> , 2021, 12, 82-89.	0.2	1

#	ARTICLE	IF	CITATIONS
487	Self-collected versus clinician-collected cervical samples for the detection of HPV infections by 14-type DNA and 7-type mRNA tests. <i>BMC Infectious Diseases</i> , 2021, 21, 504.	1.3	19
488	Clinical and analytical performance of the CLART HPV 4S assay with SurePath screening samples from the Danish cervical cancer screening program using the VALGENT framework. <i>Journal of Virological Methods</i> , 2021, 292, 114118.	1.0	2
489	Comparative analysis of different PCR-based strategies for HPV detection and genotyping from cervical samples. <i>Journal of Medical Virology</i> , 2021, 93, 6347-6354.	2.5	7
490	A prospective study of photodynamic therapy for cervical squamous intraepithelial lesion. <i>Photodiagnosis and Photodynamic Therapy</i> , 2021, 34, 102185.	1.3	16
491	Updated evidence-based recommendations for cervical cancer screening in France. <i>European Journal of Cancer Prevention</i> , 2022, 31, 279-286.	0.6	14
492	Assessing national cervical cancer screening guidelines: Results from an HIV testing clinic also screening for cervical cancer and HPV in Soweto, South Africa. <i>PLoS ONE</i> , 2021, 16, e0255124.	1.1	7
493	Age, margin status, high-risk human papillomavirus and cytology independently predict recurrent high-grade cervical intraepithelial neoplasia up to 6 years after treatment. <i>Oncology Letters</i> , 2021, 22, 684.	0.8	7
494	Performance of cervical cancer screening and triage strategies among women living with HIV in China. <i>Cancer Medicine</i> , 2021, 10, 6078-6088.	1.3	5
495	Cervical cancer screening using HPV tests on self-samples: attitudes and preferences of women participating in the VALHUDES study. <i>Archives of Public Health</i> , 2021, 79, 155.	1.0	21
496	Evaluation of HarmoniaHPV test for detection of clinically significant Human Papillomavirus infection using the VALGENT framework. <i>Journal of Virological Methods</i> , 2021, 294, 114161.	1.0	2
497	The value of adding a single co-test in HPV primary screening. <i>Preventive Medicine</i> , 2021, 149, 106617.	1.6	4
498	2020 list of human papillomavirus assays suitable for primary cervical cancer screening. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1083-1095.	2.8	116
499	Evaluating the Performance of Hybrid Capture 2 Test as a Primary Screening Test from Studies Conducted in Low and Middle-Income Country Settings- Special Focus India. <i>Asian Pacific Journal of Cancer Prevention</i> , 2021, 22, 2709-2716.	0.5	1
500	Qualitative assessment of attitudes toward cervical cancer (CC) screening and HPV self-sampling among African American (AA) and Sub Saharan African Immigrant (SAI) women. <i>Ethnicity and Health</i> , 2022, 27, 1769-1786.	1.5	1
501	HPV Genotype Specific and Age Stratified Immediate Prevalence of Cervical Precancers and Cancers in Women with NILM/hrHPV+: A Single Center Retrospective Study of 26,228 Cases. <i>Cancer Management and Research</i> , 2021, Volume 13, 6869-6877.	0.9	3
502	Clinical and analytical evaluation of the RealTime High Risk HPV assay in Colli-Pee collected first-void urine using the VALHUDES protocol. <i>Gynecologic Oncology</i> , 2021, 162, 575-583.	0.6	27
504	Prevention and Screening of HPV Malignancies. <i>Seminars in Radiation Oncology</i> , 2021, 31, 297-308.	1.0	5
505	Comparison of Alinity m HPV and cobas HPV assays on cervical specimens in diverse storage media. <i>Tumour Virus Research</i> , 2021, 12, 200224.	1.5	1

#	ARTICLE	IF	CITATIONS
506	Accuracy of combined molecular and morphology-based triage for HPV-positive women in routine cervical cancer screening services from Colombia. <i>Preventive Medicine</i> , 2021, 153, 106801.	1.6	3
507	A Cross-Sectional Study on Knowledge, Attitude and Practice on Cervical Malignancy and its Screening among Adult Women. <i>International Journal of Current Research and Review (discontinued)</i> , 2021, 13, 193-198.	0.1	0
508	Decision-making, barriers, and facilitators regarding cervical cancer screening participation among Turkish and Moroccan women in the Netherlands: a focus group study. <i>Ethnicity and Health</i> , 2022, 27, 1147-1165.	1.5	13
509	Clinical validation of the Cobas 4800 HPV assay using cervical samples in SurePath medium under the VALGENT4 framework. <i>Journal of Clinical Virology</i> , 2020, 128, 104336.	1.6	11
510	Atención en salud de mujeres con lesiones precursoras de cáncer de cuello uterino: evidencia cualitativa de la fragmentación del sistema de salud en Colombia. <i>Revista Gerencia Y Políticas De Salud</i> , 2019, 18, 1-20.	0.2	4
511	Value of Diffusion-Weighted Magnetic Resonance Imaging Combined with miR-18a Level in Predicting Radiosensitivity of Cervical Cancer. <i>Medical Science Monitor</i> , 2018, 24, 7271-7278.	0.5	7
512	Recent advances in understanding and preventing human papillomavirus-related disease. <i>F1000Research</i> , 2017, 6, 269.	0.8	7
513	Evidence-based cervical screening: experts' normative views of evidence and the role of the 'evidence-based brand'. <i>Evidence and Policy</i> , 2020, 16, 359-374.	0.5	3
514	Human Papillomavirus Prevalence in a Population of Women Living in Port-au-Prince and Leogane, Haiti. <i>PLoS ONE</i> , 2013, 8, e76110.	1.1	9
515	Human Papillomavirus Type-Specific Prevalence in the Cervical Cancer Screening Population of Czech Women. <i>PLoS ONE</i> , 2013, 8, e79156.	1.1	22
516	Triage of HR-HPV Positive Women with Minor Cytological Abnormalities: A Comparison of mRNA Testing, HPV DNA Testing, and Repeat Cytology Using a 4-Year Follow-Up of a Population-Based Study. <i>PLoS ONE</i> , 2014, 9, e90023.	1.1	23
517	Presence of High-Risk HPV mRNA in Relation to Future High-Grade Lesions among High-Risk HPV DNA Positive Women with Minor Cytological Abnormalities. <i>PLoS ONE</i> , 2015, 10, e0124460.	1.1	25
518	Minor Cytological Abnormalities and up to 7-Year Risk for Subsequent High-Grade Lesions by HPV Type. <i>PLoS ONE</i> , 2015, 10, e0127444.	1.1	7
519	Effectiveness Modelling and Economic Evaluation of Primary HPV Screening for Cervical Cancer Prevention in New Zealand. <i>PLoS ONE</i> , 2016, 11, e0151619.	1.1	49
520	Optimal Management Strategies for Primary HPV Testing for Cervical Screening: Cost-Effectiveness Evaluation for the National Cervical Screening Program in Australia. <i>PLoS ONE</i> , 2017, 12, e0163509.	1.1	26
521	Need for National Commitments to Cancer Research to Guide Public Health Investment and Practice. , 2015, , 249-262.		6
523	Evaluation of cytology versus human papillomavirus-based cervical cancer screening algorithms in Bhutan. <i>Oncotarget</i> , 2017, 8, 72438-72446.	0.8	8
524	Proteomic alterations in early stage cervical cancer. <i>Oncotarget</i> , 2018, 9, 18128-18147.	0.8	20

#	ARTICLE	IF	CITATIONS
525	HPV-FASTER: Combined strategies of HPV vaccination and HPV screening towards a one visit for cervical cancer preventive campaigns. <i>Salud Publica De Mexico</i> , 2018, 60, 612.	0.1	6
526	A Thematic Analysis of Attitudes Toward Changes to Cervical Screening in Australia. <i>JMIR Cancer</i> , 2019, 5, e12307.	0.9	18
527	Optimizing high risk HPV-based primary screening for cervical cancer in low- and middle-income countries: opportunities and challenges. <i>Minerva Ginecologica</i> , 2019, 71, 365-371.	0.8	11
528	Evidence based appropriate triage strategies for implementing high risk HPV as primary technology in cervical cancer screening. <i>Minerva Ginecologica</i> , 2020, 72, 96-105.	0.8	4
529	Randomized controlled trial evaluating the utility of urine HPV DNA for cervical cancer screening in a Pacific Island population. <i>Journal of Global Health Reports</i> , 0, 2, .	1.0	3
530	Adherence to triage among women with HPV-positive self-collection: a study in a middle-low income population in Argentina. <i>Ecancermedalscience</i> , 2020, 14, 1138.	0.6	16
531	Type-Specific Viral Load and Physical State of HPV Type 16, 18, and 58 as Diagnostic Biomarkers for High-Grade Squamous Intraepithelial Lesions or Cervical Cancer. <i>Cancer Research and Treatment</i> , 2020, 52, 396-405.	1.3	16
532	Cervical cancer screening in Switzerland: time to rethink the guidelines. <i>Swiss Medical Weekly</i> , 2015, 145, w14112.	0.8	11
533	Cross-sectional seroprevalence of antibodies against 6, 11, 16 and 18 human papilloma virus (HPV) types among teenagers and young women in Italy. <i>Annali Dell'Istituto Superiore Di Sanita</i> , 2014, 50, 171-7.	0.2	4
534	HPV Prevalence and Detection of Rare HPV Genotypes in Hong Kong Women from Southern China with Cytological Abnormalities. <i>ISRN Virology</i> , 2013, 2013, 1-5.	0.5	6
535	Population-based Cervical Cancer Screening Using High-risk HPV DNA Test and Liquid-based Cytology in Northern Thailand. <i>Asian Pacific Journal of Cancer Prevention</i> , 2014, 15, 6837-6842.	0.5	14
536	Clinical Evaluation of Human Papillomavirus Detection by careHPV <sup>TM</sup> Test on Physician-Samples and Self-Samples using The Indicating FTA Elute <sup>®</sup> Card. <i>Asian Pacific Journal of Cancer Prevention</i> , 2014, 15, 7085-7090.	0.5	16
537	CoCoss-Trial: Concurrent Comparison of Self-Sampling Devices for HPV-Detection. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 10388.	1.2	13
538	Evaluation of ILEX SelfCerv for Detection of High-Risk Human Papillomavirus Infection in Gynecology Clinic Attendees at a Tertiary Hospital in South Africa. <i>Journal of Clinical Medicine</i> , 2021, 10, 4817.	1.0	5
539	Women's acceptability of and experience with primary human papillomavirus testing for cervix screening: HPV FOCAL trial cross-sectional online survey results. <i>BMJ Open</i> , 2021, 11, e052084.	0.8	6
540	<i>Cancer Epidemiology</i> , 2014, , 2159-2189.		0
541	<i>Human Papillomaviruses</i> , 2015, , 15-43.		0
542	Histologic Outcomes in HPV-Positive and Cervical Cytology-Negative Women - Screening Results in Northern Thailand. <i>Asian Pacific Journal of Cancer Prevention</i> , 2015, 16, 7271-7275.	0.5	0

#	ARTICLE	IF	CITATIONS
543	Human Papillomaviruses (HPVs). , 2017, , 21-43.		0
544	Molecular Carcinogenesis in Gynecologic Neoplasias. , 2017, , 207-231.		0
545	Human Papillomavirus DNA Test Positivity: A Clinical Finding without Evidence of Disease. MOJ Women S Health, 2017, 4, .	0.2	0
546	Comparison and Correlation of Cytology, Colposcopy and Histopathology of Premalignant Lesions of Cervix In Rural Women of Barabanki District. IOSR Journal of Dental and Medical Sciences, 2017, 16, 13-18.	0.0	1
547	Investigation and Typing of Human Papillomavirus in Cervical Swab Samples. Journal of Gynecological Research and Obstetrics, 2017, 3, 070-074.	0.3	0
548	New Guidelines for Screening of Cervical Cancer Around the World. Journal of Obstetrics, Gynecology and Cancer Research, 2017, 2, 1-2.	0.0	0
549	Cytology and HPV Testing in Primary Cervical Cancer Screening. , 2019, , 83-91.		0
550	Eliminating Cervical Cancer: A Role for Artificial Intelligence. , 2019, , 405-422.		1
551	Overview of Cervical and Anal Cytopathology. , 2020, , 27-41.		1
552	Prevalence of high-risk human papillomavirus infection and cervical cytology abnormalities among women up to age 40 in the Tuzla Canton, Bosnia and Herzegovina. Acta Dermatovenerologica Alpina, Panonica Et Adriatica, 2020, 29, .	0.1	0
553	Accuracy of different triage strategies for human papillomavirus positivity in an Italian screening population. International Journal of Cancer, 2022, 150, 952-960.	2.3	2
554	Loop-Mediated Isothermal Amplification Assay for Detecting Tumor Markers and Human Papillomavirus: Accuracy and Supplemental Diagnostic Value to Endovaginal MRI in Cervical Cancer. Frontiers in Oncology, 2021, 11, 747614.	1.3	3
555	Community cervical cancer screening: Barriers to successful home-based HPV self-sampling in Dabat district, North Gondar, Ethiopia. A qualitative study. PLoS ONE, 2020, 15, e0243036.	1.1	21
556	Papillomaviral infection and cervical diseases in pregnant women. Risk factors of social status, reproductive and contraceptive behavior. Gynecology, 2020, 22, 74-79.	0.1	0
557	Cervical cancer screening in Romania: it is time to change. Obstetrica Si Ginecologie, 2020, 3, 134.	0.0	0
559	Risk-stratification of HPV-positive women with low-grade cytology by FAM19A4/miR124-2 methylation and HPV genotyping. British Journal of Cancer, 2022, 126, 259-264.	2.9	13
562	Functional foods and their role in cancer prevention and health promotion: a comprehensive review. American Journal of Cancer Research, 2017, 7, 740-769.	1.4	29
563	Randomized controlled trial evaluating the utility of urine HPV DNA for cervical cancer screening in a Pacific Island population. Journal of Global Health Reports, 2018, 2, .	1.0	3

#	ARTICLE	IF	CITATIONS
564	HPV negative cervical cancers and primary HPV screening. Facts, Views & Vision in ObGyn, 2018, 10, 107-113.	0.5	15
565	The IARC Perspective on Cervical Cancer Screening. New England Journal of Medicine, 2021, 385, 1908-1918.	13.9	125
566	Self-sampling as the principal modality for population based cervical screening: Five-year follow-up of the PaVDA study. International Journal of Cancer, 2022, 150, 1350-1356.	2.3	8
567	Worldwide use of HPV self-sampling for cervical cancer screening. Preventive Medicine, 2022, 154, 106900.	1.6	87
568	Papilloplex HR-HPV test has non-inferior clinical performance for detection of human papillomavirus infection: assessment using the VALGENT framework. Journal of Clinical Pathology, 2023, 76, 172-176.	1.0	0
569	A Gene Signature Identifying CIN3 Regression and Cervical Cancer Survival. Cancers, 2021, 13, 5737.	1.7	9
570	Diagnostic performance of p16/Ki-67 dual immunostaining at different number of positive cells in cervical smears in women referred for colposcopy. Radiology and Oncology, 2021, 55, 426-432.	0.6	3
571	Pre-invasive Cervical Disease and Colposcopy. , 2021, , 275-283.		0
572	HPV-Impfung: Sehr effektiv " aber immer noch vernachlässigt. , 0, , .		0
573	Effectiveness and costs of an implemented primary HPV cervical screening programme in Sweden " A population based cohort study. Preventive Medicine Reports, 2022, 25, 101675.	0.8	3
574	Analysis of cervical cancer mortality rate trends in Natal-RN, Brazil, between 2000 and 2012. Revista De Salud Publica, 2019, 21, 161-167.	0.0	4
575	Clinical utility of reflex testing with cancer biomarkers to improve diagnostic accuracy of primary Human Papillomavirus screening. Cancer Epidemiology Biomarkers and Prevention, 2022, , cebp.0972.2021.	1.1	1
576	Test of cure and beyond: superiority of thermal ablation over LLETZ in the treatment of high-grade CIN. Archives of Gynecology and Obstetrics, 2022, , .	0.8	0
577	Clinical Performance of the Full Genotyping Agena MassARRAY HPV Assay Using SurePath Screening Samples within the VALGENT4 Framework. Journal of Molecular Diagnostics, 2022, 24, 365-373.	1.2	2
578	Agreement between L1 and E6/E7-based assays for detection of high-risk HPV in cervical, oropharyngeal and penile cancers. Journal of Clinical Pathology, 2023, 76, 467-473.	1.0	3
579	Clinical Performance of DNA and RNA Based HPV Tests for Test of Cure (TOC) Post Treatment for Cervical Intraepithelial Neoplasia (CIN) - a Retrospective Study. SSRN Electronic Journal, 0, , .	0.4	0
580	Distribution of human papillomavirus genotypes in suspected women cytological specimens from Tehran, Iran. Iranian Journal of Microbiology, 0, , .	0.8	0
581	Screening technologies for cervical cancer: Overview. CytoJournal, 2022, 19, 23.	0.8	7



#	ARTICLE	IF	CITATIONS
582	Comparison of cytopathologic findings in patients with negative Pap test and positive high-risk HPV infection among three groups. <i>Archives of Gynecology and Obstetrics</i> , 2022, , 1.	0.8	0
583	Knowledge, attitude and practice of female university students regarding human papillomavirus and self-sampling in KwaZulu-Natal, South Africa: a cross-sectional survey. <i>BMC Women's Health</i> , 2022, 22, 58.	0.8	4
584	Risk of recurrent disease following conization of cervical intraepithelial neoplasia grade 3 according to post-conization HPV status and surgical margins. <i>Gynecologic Oncology</i> , 2022, 165, 472-477.	0.6	4
585	Comparative performance of the human papillomavirus test and cytology for primary screening for high-grade cervical intraepithelial neoplasia at the population level. <i>International Journal of Cancer</i> , 2022, 150, 1422-1430.	2.3	4
586	Clinical performance of DNA and RNA based HPV tests for Test of Cure (TOC) post treatment for cervical intraepithelial neoplasia (CIN) - a retrospective study.. <i>Journal of Clinical Virology</i> , 2022, 150-151, 105165.	1.6	0
587	Randomized controlled trial evaluating the utility of urine HPV DNA for cervical cancer screening in a Pacific Island population. <i>Journal of Global Health Reports</i> , 0, , .	1.0	0
588	Cervical Cancer Screening with HPV Testing: Updates on the Recommendation. <i>Revista Brasileira De Ginecologia E Obstetricia</i> , 2022, 44, 264-271.	0.3	4
589	Cervical, vaginal and vulvar cancer incidence and survival trends in Denmark, Finland, Norway and Sweden with implications to treatment. <i>BMC Cancer</i> , 2022, 22, 456.	1.1	9
590	Clinical Performance of Triage Strategies for Hr-HPV-Positive Women; A Longitudinal Evaluation of Cytology, p16/K-67 Dual Stain Cytology, and HPV16/18 Genotyping. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 1492-1498.	1.1	4
591	Experience destructive therapy anogenital warts. <i>Vestnik Dermatologii I Venerologii</i> , 2016, 92, 96-101.	0.2	1
592	Molecular Epidemiology of Human Papillomavirus Infection Among Chinese Women With Cervical Cytological Abnormalities. <i>Frontiers in Public Health</i> , 2022, 10, .	1.3	3
593	A cationic amino acid polymer nanocarrier synthesized in supercritical CO2 for co-delivery of drug and gene to cervical cancer cells. <i>Colloids and Surfaces B: Biointerfaces</i> , 2022, 216, 112584.	2.5	12
594	Effectiveness and Safety of Therapeutic Vaccines for Precancerous Cervical Lesions: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
595	Accuracy and effectiveness of HPV mRNA testing in cervical cancer screening: a systematic review and meta-analysis. <i>Lancet Oncology</i> , The, 2022, 23, 950-960.	5.1	28
596	Relationship between positive margin and residual/recurrence after excision of cervical intraepithelial neoplasia: a systematic review and meta-analysis. <i>Translational Cancer Research</i> , 2022, 11, 1762-1769.	0.4	1
597	Risk factors analysis of recurrent disease after treatment with a loop electrosurgical excision procedure for high-grade cervical intraepithelial neoplasia. <i>International Journal of Gynecology and Obstetrics</i> , 2023, 160, 538-547.	1.0	7
598	A Home-Mailed Versus General Practitioner-Delivered Vaginal Self-Sampling Kit for Cervical Cancer Screening: A Cluster Randomized Controlled Trial with a Cost-Effectiveness Analysis. <i>Journal of Women's Health</i> , 0, , .	1.5	0
599	Cervical cancer screening programmes and age-specific coverage estimates for 202 countries and territories worldwide: a review and synthetic analysis. <i>The Lancet Global Health</i> , 2022, 10, e1115-e1127.	2.9	118

#	ARTICLE	IF	CITATIONS
600	Cervical cancer screening in low- and middle-income countries: A systematic review of economic evaluation studies. <i>Clinics</i> , 2022, 77, 100080.	0.6	6
601	Distribution of human papillomavirus genotypes by severity of cervical lesions in HPV screened positive women from the ESTAMPA study in Latin America. <i>PLoS ONE</i> , 2022, 17, e0272205.	1.1	13
602	HPV-Vaccine Hesitancy in Colombia: A Mixed-Methods Study. <i>Vaccines</i> , 2022, 10, 1187.	2.1	3
604	Randomized Implementation of a Primary Human Papillomavirus Testing-based Cervical Cancer Screening Protocol for Women 34 to 69 Years in Norway. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 1812-1822.	1.1	6
605	Results from a cervical cancer screening program in Samsun, Turkey. <i>BMC Women's Health</i> , 2022, 22, .	0.8	2
606	Predictors of treatment failure for adenocarcinoma in situ of the uterine cervix: Up to 14 years of recorded follow-up. <i>Oncology Letters</i> , 2022, 24, .	0.8	3
607	Cervical cancer screening, treatment and prophylaxis in Brazil: Current and future perspectives for cervical cancer elimination. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	6
609	Alternative cytology triage strategies for primary HPV screening. <i>Gynecologic Oncology</i> , 2022, 167, 73-80.	0.6	2
610	Rapid and simultaneous visual typing of high-risk HPV-16/18 with use of integrated lateral flow strip platform. <i>Mikrochimica Acta</i> , 2022, 189, .	2.5	5
611	Clinical performance of the Roche Cobas 4800 HPV test for primary cervical cancer screening in a Chinese population. <i>PLoS ONE</i> , 2022, 17, e0272721.	1.1	3
612	Analytical and clinical performance of extended HPV genotyping with BD Onclarity HPV Assay in home-collected first-void urine: A diagnostic test accuracy study. <i>Journal of Clinical Virology</i> , 2022, 155, 105271.	1.6	13
613	Harms and benefits of cervical cancer screening among non-attenders in Switzerland: The transition towards HPV-based screening. <i>Preventive Medicine Reports</i> , 2022, 29, 101929.	0.8	1
614	Pregnancy outcome and risk of recurrence after tissue-preserving loop electrosurgical excision procedure (LEEP). <i>Archives of Gynecology and Obstetrics</i> , 2023, 307, 1137-1143.	0.8	3
615	Clinical Performance of the RealTime High Risk HPV Assay on Self-Collected Vaginal Samples within the VALHUDES Framework. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	8
616	HPV Test as Test of Cure After Conization for CIN2+: A Nationwide Register-Based Cohort Study. <i>Journal of Lower Genital Tract Disease</i> , 2022, 26, 287-292.	0.9	4
617	IPVS Policy Statement on HPV Nucleic Acid Testing Guidance for Those Utilising/Considering HPV as Primary Precancer Screening: Quality Assurance and Quality Control Issues. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
618	Full genotyping and FAM19A4/miR124-2 methylation analysis in high-risk human papillomavirus-positive samples from women over 30 years participating in cervical cancer screening in Årrebo, Sweden. <i>PLoS ONE</i> , 2022, 17, e0274825.	1.1	1
619	Practical Model for Residual/Recurrent Cervical Intraepithelial Lesions in Patients with Negative Margins after Cold-Knife Conization. <i>Journal of Clinical Medicine</i> , 2022, 11, 5634.	1.0	1

#	ARTICLE	IF	CITATIONS
620	Validation of BD Onclarity HPV Assay on Vaginal Self-Samples versus Cervical Samples Using the VALHUDES Protocol. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 2177-2184.	1.1	11
621	Genotyping and Cytology Triage of High-Risk HPV DNA Positive Women for Detection of Cervical High-Grade Lesions. <i>Journal of Lower Genital Tract Disease</i> , 0, Publish Ahead of Print, .	0.9	1
622	Certification as dysplasia unit and its impact on large loop electrosurgical excision (LEEP). <i>Archives of Gynecology and Obstetrics</i> , 0, , .	0.8	0
623	Evaluation of a Web-Based Culturally Sensitive Educational Video to Facilitate Informed Cervical Cancer Screening Decisions Among Turkish- and Moroccan-Dutch Women Aged 30 to 60 Years: Randomized Intervention Study. <i>Journal of Medical Internet Research</i> , 2022, 24, e35962.	2.1	5
624	Analysis of the Results of Severe Intraepithelial Squamous Cell Lesions and Preinvasive Cervical Cancer Phototheranostics in Women of Reproductive Age. <i>Biomedicines</i> , 2022, 10, 2521.	1.4	3
625	Effectiveness of Cervical Testing in and outside a Screening Program—A Case-Control Study. <i>Cancers</i> , 2022, 14, 5193.	1.7	2
626	Risk of cervical precancer among HPV—negative women in the Netherlands and its association with previous HPV and cytology results: A follow-up analysis of a randomized screening study. <i>PLoS Medicine</i> , 2022, 19, e1004115.	3.9	2
627	Recent HPV self-sampling use for cervical cancer screening in Latin America and Caribbean: a systematic review. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
628	P16/Ki-67 Dual Staining in Positive Human Papillomavirus DNA Testing for Predictive Diagnosis of Abnormal Cervical Lesions in Northeastern Thai Women. <i>Asian Pacific Journal of Cancer Prevention</i> , 2022, 23, 3405-3411.	0.5	4
630	Implementing HPV testing in 9 Latin American countries: The laboratory perspective as observed in the ESTAMPA study. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	2
631	Time trend and Age-Period-Cohort analysis of potentially HPV-related oral and pharyngeal cancer incidence in Singapore between 1968 and 2017. <i>Oral Oncology</i> , 2023, 136, 106272.	0.8	3
632	Risk Factors Associated with CIN2+ in Spanish Patients with L-SIL/ASCUS Cytology Collected from a Madrid Hospital. <i>Journal of Personalized Medicine</i> , 2022, 12, 1944.	1.1	0
633	IPVS POLICY STATEMENT ON HPV NUCLEIC ACID TESTING guidance for those utilising/considering HPV as primary precancer screening: Quality Assurance and Quality Control issues.. <i>Journal of Clinical Virology</i> , 2022, , 105349.	1.6	6
634	Factors Associated with the Uptake of Genetic Testing for Cancer Risks: A Pathway Analysis Using the Health Information National Trends Survey Data. <i>Life</i> , 2022, 12, 2024.	1.1	0
635	Evaluation of the clinical performance of OncoPredict HPV—SCR assay within the VALGENT— framework. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	0
636	Offering HPV self-sampling kits: an updated meta-analysis of the effectiveness of strategies to increase participation in cervical cancer screening. <i>British Journal of Cancer</i> , 2023, 128, 805-813.	2.9	20
637	Experiences of human papillomavirus self—sampling by women >60 years old:— qualitative study. <i>Health Expectations</i> , 2023, 26, 818-826.	1.1	2
638	Correlation of immediate prevalence of cervical precancers and cancers with HPV genotype and age in women with ASC-US/hrHPV+: a retrospective analysis of 2292 cases. <i>Journal of Clinical Pathology</i> , 0, , jcp-2022-208580.	1.0	0

#	ARTICLE	IF	CITATIONS
640	Detection of high-grade cervical neoplasia using extended genotyping: Performance data from the longitudinal phase of the Onclarity trial. <i>Gynecologic Oncology</i> , 2023, 170, 143-152.	0.6	2
641	AACC Guidance Document on Cervical Cancer Detection: Screening, Surveillance, and Diagnosis. <i>Journal of applied laboratory medicine</i> , The, 2023, 8, 382-406.	0.6	1
642	Cervical HPV infection in Guangzhou, China: an epidemiological study of 198,111 women from 2015 to 2021. <i>Emerging Microbes and Infections</i> , 2023, 12, .	3.0	8
643	HPV-based Cervical Cancer Screening on Self-samples in the Netherlands: Challenges to Reach Women and Test Performance Questions. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2023, 32, 159-163.	1.1	5
645	The Significance of Cytology, Biopsy, and HPV Testing. , 2023, , 67-105.		0
646	Quality assurance in human papillomavirus testing for primary cervical screening. <i>International Journal of Gynecological Cancer</i> , 2023, 33, 802-811.	1.2	9
647	Artificial intelligence in colposcopic examination: A promising tool to assist junior colposcopists. <i>Frontiers in Medicine</i> , 0, 10, .	1.2	3
648	Reproductive and Obstetric Outcomes after Fertility-Sparing Treatments for Cervical Cancer: Current Approach and Future Directions. <i>Journal of Clinical Medicine</i> , 2023, 12, 2614.	1.0	1
649	Validation of a questionnaire for young women to assess knowledge, attitudes and behaviors towards cervical screening and vaccination against HPV: survey among an Italian sample. , 2022, 11, .		5
657	HPV-Testverfahren. , 2023, , 99-108.		0
658	Human Papillomavirus Vaccines. , 2023, , 484-513.e11.		0
667	<i>Cancer Epidemiology</i> . , 2023, , 1-43.		0
682	Accuracy of HPV E6/E7 oncoprotein tests to detect high-grade cervical lesions: a systematic literature review and meta-analysis. <i>British Journal of Cancer</i> , 2024, 130, 517-525.	2.9	1